

1214917

THE UNITED STATES OF AMERICA

TO ALL TO WHOM THESE PRESENTS SHALL COME:

UNITED STATES DEPARTMENT OF COMMERCE

United States Patent and Trademark Office

August 23, 2004

THIS IS TO CERTIFY THAT ANNEXED HERETO IS A TRUE COPY FROM THE RECORDS OF THE UNITED STATES PATENT AND TRADEMARK OFFICE OF THOSE PAPERS OF THE BELOW IDENTIFIED PATENT APPLICATION THAT MET THE REQUIREMENTS TO BE GRANTED A FILING DATE UNDER 35 USC 111.

APPLICATION NUMBER: 60/491,968

FILING DATE: *August 04, 2003*

Certified by



Jon W Dudas

Acting Under Secretary of Commerce
for Intellectual Property
and Acting Director of the U.S.
Patent and Trademark Office

PROVISIONAL APPLICATION FOR PATENT COVER SHEET

This is a request for filing a PROVISIONAL APPLICATION FOR PATENT under 37 CFR 1.53 (c).

Express Mail Label No.

INVENTOR(S)					
Given Name (first and middle (if any))	Family Name or Surname	Residence (City and either State or Foreign Country)			
STEPHEN W. BERGE A.	SCHERER MINASSIAN	Toronto, Ontario, Canada Toronto, Ontario, Canada			
<input type="checkbox"/> Additional inventors are being named on the _____ separately numbered sheets attached hereto					
TITLE OF THE INVENTION (280 characters max)					
LAFORA'S DISEASE GENE					
CORRESPONDENCE ADDRESS					
Direct all correspondence to:					
<input checked="" type="checkbox"/> Customer Number	1059	Place Customer Number Bar Code Label here			
OR Type Customer Number here					
<input checked="" type="checkbox"/> Firm or Individual Name	BERESKIN & PARR				
Address	40 King Street West				
Address					
City	Toronto	State	Ontario	ZIP	M5H 3Y2
Country	Canada	Telephone	416-364-7311	Fax	416-361-1398
ENCLOSED APPLICATION PARTS (check all that apply)					
<input checked="" type="checkbox"/> Specification Number of Pages	62	<input type="checkbox"/> CD(s), Number			
<input checked="" type="checkbox"/> Drawing(s) Number of Sheets	11	<input type="checkbox"/> Other (specify)			
<input checked="" type="checkbox"/> Application Data Sheet. See 37 CFR 1.76					
METHOD OF PAYMENT OF FILING FEES FOR THIS PROVISIONAL APPLICATION FOR PATENT					
<input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27.					
<input checked="" type="checkbox"/> A check or money order is enclosed to cover the filing fees					
<input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge filing fees or credit any overpayment to Deposit Account Number: 022095					
<input type="checkbox"/> Payment by credit card. Form PTO-2038 is attached.					
FILING FEE AMOUNT (\$) 160.00					
The invention was made by an agency of the United States Government or under a contract with an agency of the United States Government.					
<input checked="" type="checkbox"/> No.					
<input type="checkbox"/> Yes, the name of the U.S. Government agency and the Government contract number are: _____					

Respectfully submitted,
SIGNATURE

VK

Date AUG. 1, 2003

TYPED or PRINTED NAME VICTOR KRICKER

REGISTRATION NO. 50,198
(if appropriate)

TELEPHONE 416-364-7311

Docket Number: 9962-51

USE ONLY FOR FILING A PROVISIONAL APPLICATION FOR PATENT

This collection of information is required by 37 CFR 1.51. The information is used by the public to file (and by the PTO to process) a provisional application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 8 hours to complete, including gathering, preparing, and submitting the complete provisional application to the PTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C., 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Box Provisional Application, Assistant Commissioner for Patents, Washington, D.C. 20231.

19507 U.S. PTO
60/491968

08/04/03

16698 U.S. PAT. & TM. OFF. FORM 1001-101 08/04/03

PTO/SB/17 (01-03)

Approved for use through 01/31/2003, OMB 0651-0032
U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

FEE TRANSMITTAL for FY 2003

Patent fees are subject to annual revision.

☐ Applicant claims small entity status. See 37 CFR 1.27

TOTAL AMOUNT OF PAYMENT (\$)

160.00

Complete if Known

Application Number
Filing Date
First Named Inventor STEPHEN W. SCHERER
Examiner Name
Art Unit
Attorney Docket No. 9962-51

METHOD OF PAYMENT (check all that apply)

☒ Check ☐ Credit card ☐ Money Order ☐ Other ☐ None

☒ Deposit Account:

Deposit Account Number
Deposit Account Name

022095

Bereskin & Parr

The Commissioner is authorized to: (check all that apply)

☒ Charge fee(s) indicated below ☐ Credit any overpayments
☐ Charge any additional fee(s) during the pendency of this application
☐ Charge fee(s) indicated below, except for the filing fee to the above-identified deposit account.

FEE CALCULATION

1. BASIC FILING FEE

Large Entity Fee Code (\$)	Small Entity Fee Code (\$)	Fee Description	Fee Paid
1001 750	2001 375	Utility filing fee	
1002 330	2002 165	Design filing fee	
1003 520	2003 260	Plant filing fee	
1004 750	2004 375	Reissue filing fee	
1005 160	2005 80	Provisional filing fee	160.00
SUBTOTAL (1) (\$)			160.00

2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE

Total Claims - 20 ** = X =
Independent Claims - 3 ** = X =
Multiple Dependent =

Large Entity		Small Entity		Fee Description
Fee Code	Fee (\$)	Fee Code	Fee (\$)	
1202	18	2202	9	Claims in excess of 20
1201	84	2201	42	Independent claims in excess of 3
1203	280	2203	140	Multiple dependent claim, if not paid
1204	84	2204	42	** Reissue independent claims over original patent
1205	18	2205	9	** Reissue claims in excess of 20 and over original patent

**or number previously paid, if greater; For Reissues, see above

FEE CALCULATION (continued)

3. ADDITIONAL FEES

Large Entity Small Entity

Fee Code (\$)	Fee Code (\$)	Fee Description	Fee Paid
1051 130	2051 65	Surcharge - late filing fee or oath	
1052 50	2052 25	Surcharge - late provisional filing fee or cover sheet	
1053 130	1053 130	Non-English specification	
1812 2,520	1812 2,520	For filing a request for ex parte reexamination	
1804 920*	1804 920*	Requesting publication of SIR prior to Examiner action	
1805 1,840*	1805 1,840*	Requesting publication of SIR after Examiner action	
1251 110	2251 55	Extension for reply within first month	
1252 410	2252 205	Extension for reply within second month	
1253 930	2253 465	Extension for reply within third month	
1254 1,450	2254 725	Extension for reply within fourth month	
1255 1,970	2255 985	Extension for reply within fifth month	
1401 320	2401 160	Notice of Appeal	
1402 320	2402 160	Filing a brief in support of an appeal	
1403 280	2403 140	Request for oral hearing	
1451 1,510	1451 1,510	Petition to institute a public use proceeding	
1452 110	2452 55	Petition to revive - unavoidable	
1453 1,300	2453 650	Petition to revive - unintentional	
1501 1,300	2501 650	Utility issue fee (or reissue)	
1502 470	2502 235	Design issue fee	
1503 630	2503 315	Plant issue fee	
1460 130	1460 130	Petitions to the Commissioner	
1807 50	1807 50	Processing fee under 37 CFR 1.17(q)	
1806 180	1806 180	Submission of Information Disclosure Stmt	
8021 40	8021 40	Recording each patent assignment per property (times number of properties)	
1809 750	2809 375	Filing a submission after final rejection (37 CFR 1.129(a))	
1810 750	2810 375	For each additional invention to be examined (37 CFR 1.129(b))	
1801 750	2801 375	Request for Continued Examination (RCE)	
1802 900	1802 900	Request for expedited examination of a design application	

Other fee (specify)

*Reduced by Basic Filing Fee Paid

SUBTOTAL (3) (\$)

0

SUBMITTED BY

Name (Print/Type) VICTOR KRICKER

Registration No. 50,198
(Attorney/Agent)

(Complete if applicable)

Telephone (416) 364-7311

Signature

Date AUGUST 1, 2003

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

This collection of information is required by 37 CFR 1.17 and 1.27. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

B&P File No. 9962-51

BERESKIN & PARR

UNITED STATES PROVISIONAL

Title: LAFORA'S DISEASE GENE

Inventors: STEPHEN W. SCHERER and BERGE A. MINASSIAN

TITLE: LAFORA'S DISEASE GENE

FIELD OF THE INVENTION

The invention relates to a novel gene, *EPM2B*, that is involved in
5 Lafora's disease; the protein, malin, encoded by the gene; and methods of
diagnosing and treating Lafora's disease.

BACKGROUND OF THE INVENTION

Lafora's disease (LD, OMIM 254780) is the most common and severe
form of adolescent-onset progressive epilepsy. Increasing seizures are
10 paralleled with an insidious cognitive decline towards dementia, and death
usually within 10 years of onset (1,2). At the cellular level, LD is characterized
by an endoplasmic reticulum (ER)-associated accumulation (3) of starch-like
glucose polymers (4) called polyglucosans (or Lafora bodies). Inheritance is
autosomal recessive with genetic heterogeneity but the clinical presentation is
15 homogeneous (5). The inventors previously discovered that mutations in the
EPM2A gene on chromosome 6q24 encoding a dual-specificity phosphatase
(named Laforin) with a carbohydrate binding domain, cause LD (6,7).

There is a need in the art to identify other genes involved in Lafora's
disease to assist in the diagnosis and treatment of Lafora's disease.

20 **SUMMARY OF THE INVENTION**

The present inventors positionally cloned a novel gene, *EPM2B*, on
chromosome 6p22.3. It encodes a protein with a putative RING-finger domain
and 6 NHL-motifs, which are features of complexes designed for ubiquitin-
mediated regulation of specific substrates (8,9) and protein-protein
25 interactions (10-13), respectively. Seventeen distinct DNA sequence
variations in *EPM2B* predicted to cause deleterious effects on the protein
product, named malin, were found to co-segregate with LD in 26 families.
Both laforin and malin localize to the ER suggesting they operate in a related
pathway protecting against neuronal polyglucosan accumulation and epilepsy.
30 The inventors have also isolated and sequenced the canine version of
EPM2B.

Accordingly, the present invention provides an isolated nucleic acid
molecule that is associated with Lafora's disease and having the sequence

shown in SEQ ID NO:1 (Figure 6A). The present invention also provides an isolated nucleic acid molecule having a sequence shown in SEQ ID NO:3 (Figure 7A).

Preferably, the purified and isolated nucleic acid molecule comprises:

- 5 (a) a nucleic acid sequence as shown in SEQ ID NO:1 (Figure 6A) and SEQ ID NO:3 (Figure 7A), wherein T can also be U;
- (b) a nucleic acid sequence complementary to (a);
- (c) a nucleic acid sequence that has substantial sequence homology to a nucleic acid sequence of (a) or (b);
- 10 (d) a nucleic acid sequence that is an analog of a nucleic acid sequence of (a), (b) or (c); or
- (e) a nucleic acid sequence that hybridizes to a nucleic acid sequence of (a), (b), (c) or (d) under stringent hybridization conditions.

The present invention also includes an isolated protein containing a
15 zinc finger of the RING type and 6 NHL-repeat domains which is associated with Lafora's disease. In a preferred embodiment of the invention, the protein has the amino acid sequence as shown in SEQ ID NO:2 (Figure 6B). In another embodiment, the protein has the amino acid sequence shown in SEQ ID NO:4 (Figure 7B).

20 As shown in Table 1, the inventors have found 17 different mutations in the *EPM2B* gene that are associated with Lafora's disease. Accordingly, the present invention provides a method of detecting Lafora's disease comprising detecting a mutation in the *EPM2B* gene in a sample from a mammal. In a preferred embodiment, the mutation is one listed in Table 1.

25 Other features and advantages of the present invention will become apparent from the following detailed description. It should be understood, however, that the detailed description and the specific examples while indicating preferred embodiments of the invention are given by way of illustration only, since various changes and modifications within the spirit and
30 scope of the invention will become apparent to those skilled in the art from this detailed description.

BRIEF DESCRIPTION OF THE DRAWINGS

The invention will now be described in relation to the drawings in which:

Figure 1. The *EPM2B* region on 6p22.3. The previous 2.2 Mb critical interval was delimited by microsatellite markers *D6S1567* and *BV012568* (15). The *BV012568* boundary was based on loss of homozygosity in LD individuals from an F-C family (LD6; see Fig. 2). The *D6S1567* telomeric boundary was defined by a recombination occurring between *BV012563* and *D6S1567* in an unaffected sibling of a second consanguineous F-C family (15) (LD27). A break in the chain of homozygosity of markers in the LD38324 family allowed the centromeric boundary to be further re-defined to *D6S1688* (Figure 2) The region contains 7 previously annotated genes and the newly discovered *EPM2B* (Figure 6A), which comprised of a single 1188bp coding exon. Representative human and mouse cDNA sequences are shown, as are the putative ATG start and AATAAA polyadenylation signals. The ATG start follows an in-frame stop (at position -60) and the corresponding AUG is present at the beginning of the predicted ORF. The nucleotide sequence surrounding the start (CGCGCCAUGG) has the proposed features of the consensus sequence (GCCA/GCCAUGG) of an eukaryotic translation initiation site (29). *EPM2B* is predicted to encode a 42.3 kDa (395 aa) protein (malin) containing detectable zinc-binding RING-finger and 6 NHL-repeat domains (FIGURE 6B). The RING and NHL acronyms arise from descriptions of the first proteins identified to carry them, namely, the Really Interesting New Gene 1 in *Homo sapiens* (30) and the NCL-1 (11)/HT2A (10)/LIN-41 (13) genes, respectively. It should be noted that RING- and/or NHL- domains occur in a variety of proteins which can have one or both of cytoplasmic or nuclear localization (8,9,12,18). Malin is the only protein so far described having RING and NHL motifs only (there are other proteins with this combination but they also have other associated motifs such as RING-B-Box-coiled-coil domains). The site of a common C332T (P111L) polymorphism is shown by an asterisk (*) (see Table 1). Malin shares 79%, 80%, and 85% homology with the predicted rat (419 aa), mouse (401 aa) and dog (402 aa)

proteins, respectively. The variable amino acids were primarily located in the carboxy- and amino- ends of the protein and not in the RING finger or NHL domains. The microsatellite markers beginning with BV- were generated in this study.

- 5 Figure 2. Refinement of the *EPM2B* critical interval by haplotype analysis in LD families and mutations in the *EPM2B* gene. **a**, The centromeric boundary was narrowed to *D6S1688* refining the critical region to 840 kb based on the loss of homozygosity in both probands in family LD38324. **b**, Sequence analysis of *EPM2B* identifies a homozygous 76T>A change in
10 family LD6 (as well as in the LD7, LD27, and LD28 F-C families, Table 1). Affected individuals in family LD38324 were found to be homozygous for a dinucleotide deletion (1048-1049delGA) leading to frame-shift mutation in the fifth NHL domain.

- Figure 3. RNA hybridization expression analysis of *EPM2B* in human
15 tissues. **a**, A multiple tissue blot (Clontech) was hybridized with a 557bp fragment of the coding region of *EPM2B*. Two transcripts 2.4 kb and 1.5 kb in size were identified in all tissues. **b**, The same sized transcripts were found in tissues from all regions of the brain tested.

- Figure 4. Electron micrograph of brain biopsy material from patient
20 LD32817 (*EPM2B* mutation 98T>C). **A**, axon (note the numerous normal neurotransmitter vesicles); **S**, synapse; **LB**, Lafora body (large rounded structure) composed of a dense accumulation of polyglucosan filaments (PG) completely occupying the dendrite. Bar equals 500nm.

- Figure 5. Cellular localization of the malin and laforin proteins. **a**, Myc-
25 tagged malin (construct pcDNA3myc*EPM2B*) forms a distinct reticular pattern around the nucleus, as well as within the nucleus. Co-staining with antibody against the GRP94 endoplasmic reticulum (ER)-specific marker reveals co-localization with malin. **b**, Co-localization of the cytoplasmic isoform of laforin (construct pcDNA3myc*EPM2A* (24)) with the ER-specific marker GRP94.

- 30 Figures 6A and B (SEQ ID NOS:1 and 2) provides the human nucleic acid and amino acid sequence of *EPM2B*.

Figures 7A and B (SEQ ID NOS:3 and 4) provides the canine nucleic acid and amino acid sequence for *EPM2B*.

DETAILED DESCRIPTION OF THE INVENTION

Previous studies by the inventors suggested that ~70% of LD patients
5 carry recessive mutations in the *EPM2A* gene on chromosome 6q24 (6,7,14).
To identify the causative gene(s) in the remaining patients, the inventors
initially performed linkage and homozygosity mapping on a subset of the non-
EPM2A LD families (LD6, LD7, LD27, LD28) originating from a French-
Canadian (F-C) isolate (15) (Table 1). This approach led to the localization of
10 a second LD locus (*EPM2B*) to a 2.2 Mb region on chromosome 6p22.3
(Figure 1). All affected individuals from these F-C families were found to be
homozygous for a rare haplotype across the entire critical interval (Figure 2a).
To further refine the locus, five additional LD families having multiply affected
siblings were examined using every microsatellite marker that could be
15 developed from the DNA sequence encompassing the critical region. In four
families, all affected individuals were homozygous for all markers across the
critical interval. In one family (LD38324), however, the chain of homozygosity
in two affected individuals extended only partially into the critical region
allowing reduction of the *EPM2B* locus to 840 kb between *D6S1688* and
20 *D6S1567* (Figures 1 and 2a).

I. NUCLEIC ACID MOLECULES OF THE INVENTION

As hereinbefore mentioned, the present invention relates to isolated
nucleic acid molecules that are involved in Lafora's disease. The term
"isolated" refers to a nucleic acid substantially free of cellular material or
25 culture medium when produced by recombinant DNA techniques, or chemical
precursors, or other chemicals when chemically synthesized. The term
"nucleic acid" is intended to include DNA and RNA and can be either double
stranded or single stranded.

Broadly stated, the present invention provides an isolated nucleic acid
30 molecule encoding a protein containing a zinc finger of the RING type in the
N-terminal portion and 6 NHL-repeat domains in the C-terminal portion which
is associated with Lafora's disease. The isolated nucleic acid molecule is

preferably the *EPM2B* gene associated with Lafora's disease. In an embodiment of the invention, the isolated nucleic acid molecule has a sequence as shown in SEQ ID NO:1 (Figure 6A) and SEQ ID NO:3 (Figure 7A).

5 The nucleic acid sequences shown in SEQ ID NOS:1 and 3 (or Figures 6A and 7A, respectively) as well as the mutated sequences specified in Table 1 can be collectively referred to herein as "the nucleic acid molecules of the invention". The amino acid sequences shown in SEQ ID NOS:2 and 4 (or Figures 6B and 7B, respectively) as well as the mutated sequences specified
10 in Table 1 can be collectively referred to herein as the "proteins of the invention".

 Preferably, the purified and isolated nucleic acid molecule comprises

- (a) a nucleic acid sequence as shown in SEQ ID NO:1 (Figure 6A) and SEQ ID NO:3 (Figure 7A), wherein T can also be U;
- 15 (b) a nucleic acid sequence complementary to (a);
- (c) a nucleic acid sequence that has substantial sequence homology to a nucleic acid sequence of (a) or (b);
- (d) a nucleic acid sequence that is an analog of a nucleic acid sequence of (a), (b) or (c); or
- 20 (e) a nucleic acid sequence that hybridizes to a nucleic acid sequence of (a), (b), (c) or (d) under stringent hybridization conditions.

 The term "sequence that has substantial sequence homology" means those nucleic acid sequences which have slight or inconsequential sequence variations from the sequences in (a) or (b), i.e., the sequences function in
25 substantially the same manner and can be used to detect, study or treat Lafora's disease. The variations may be attributable to local mutations or structural modifications. Nucleic acid sequences having substantial homology include nucleic acid sequences having at least 65%, more preferably at least 85%, and most preferably 90-95% identity with the nucleic acid sequences as
30 shown in SEQ ID NO:1 or SEQ ID NO:3.

 The term "sequence that hybridizes" means a nucleic acid sequence that can hybridize to a sequence of (a), (b), (c) or (d) under stringent

hybridization conditions. Appropriate "stringent hybridization conditions" which promote DNA hybridization are known to those skilled in the art, or may be found in Current Protocols in Molecular Biology, John Wiley & Sons, N.Y. (1989), 6.3.1-6.3.6. For example, the following may be employed: 6.0 x sodium chloride/sodium citrate (SSC) at about 45°C, followed by a wash of 2.0 x SSC at 50°C; 0.2 x SSC at 50°C to 65°C; or 2.0 x SSC at 44°C to 50°C. The stringency may be selected based on the conditions used in the wash step. For example, the salt concentration in the wash step can be selected from a high stringency of about 0.2 x SSC at 50°C. In addition, the temperature in the wash step can be at high stringency conditions, at about 65°C.

The term "a nucleic acid sequence which is an analog" means a nucleic acid sequence which has been modified as compared to the sequence of (a), (b) or (c) wherein the modification does not alter the utility of the sequence as described herein. The modified sequence or analog may have improved properties over the sequence shown in (a), (b) or (c). One example of a modification to prepare an analog is to replace one of the naturally occurring bases (i.e. adenine, guanine, cytosine or thymidine) of the sequence shown in SEQ ID NO:1 or 3, with a modified base such as such as xanthine, hypoxanthine, 2-aminoadenine, 6-methyl, 2-propyl and other alkyl adenines, 5-halo uracil, 5-halo cytosine, 6-aza uracil, 6-aza cytosine and 6-aza thymine, pseudo uracil, 4-thiouracil, 8-halo adenine, 8-aminoadenine, 8-thiol adenine, 8-thiolalkyl adenines, 8-hydroxyl adenine and other 8-substituted adenines, 8-halo guanines, 8 amino guanine, 8-thiol guanine, 8-thiolalkyl guanines, 8-hydroxyl guanine and other 8-substituted guanines, other aza and deaza uracils, thymidines, cytosines, adenines, or guanines, 5-trifluoromethyl uracil and 5-trifluoro cytosine.

Another example of a modification is to include modified phosphorous or oxygen heteroatoms in the phosphate backbone, short chain alkyl or cycloalkyl intersugar linkages or short chain heteroatomic or heterocyclic intersugar linkages in the nucleic acid molecule shown in SEQ ID NO:1 or SEQ ID NO:3. For example, the nucleic acid sequences may contain

phosphorothioates, phosphotriesters, methyl phosphonates, and phosphorodithioates.

A further example of an analog of a nucleic acid molecule of the invention is a peptide nucleic acid (PNA) wherein the deoxyribose (or ribose) phosphate backbone in the DNA (or RNA), is replaced with a polyamide backbone which is similar to that found in peptides (P.E. Nielsen, et al Science 1991, 254, 1497). PNA analogs have been shown to be resistant to degradation by enzymes and to have extended lives *in vivo* and *in vitro*. PNAs also bind stronger to a complimentary DNA sequence due to the lack of charge repulsion between the PNA strand and the DNA strand. Other nucleic acid analogs may contain nucleotides containing polymer backbones, cyclic backbones, or acyclic backbones. For example, the nucleotides may have morpholino backbone structures (U.S. Pat. No. 5,034,506). The analogs may also contain groups such as reporter groups, a group for improving the pharmacokinetic or pharmacodynamic properties of nucleic acid sequence.

It will be appreciated that the invention includes nucleic acid molecules encoding truncations of proteins of the invention, and analogs and homologs of proteins of the invention and truncations thereof, as described below. It will further be appreciated that variant forms of nucleic acid molecules of the invention which arise by alternative splicing of an mRNA corresponding to a cDNA of the invention are encompassed by the invention.

Isolated and purified nucleic acid molecules having sequences which differ from the nucleic acid sequence of the invention due to degeneracy in the genetic code are also within the scope of the invention. Such nucleic acids encode functionally equivalent proteins but differ in sequence from the above mentioned sequences due to degeneracy in the genetic code.

The invention also includes an isolated nucleic molecule that has a mutation as compared to the nucleic acid molecule shown in SEQ ID NO:1 (Figure 6A) or SEQ ID NO:3 (Figure 7A), wherein said mutation is associated with Lafora's disease. In a preferred embodiment, the mutation is selected from one of the mutations shown in Table 1.

Nucleic acid molecules from the *EPM2B* gene or mutated forms thereof can be isolated by preparing a labelled nucleic acid probe based on all or part of the nucleic acid sequences as shown in SEQ ID NO:1 (Figure 6A) and SEQ ID NO:3 (Figure 7A) or a mutated sequence shown in Table 1, and using this
5 labelled nucleic acid probe to screen an appropriate DNA library (e.g. a cDNA or genomic DNA library). Nucleic acids isolated by screening of a cDNA or genomic DNA library can be sequenced by standard techniques.

Nucleic acid molecules of the invention can also be isolated by selectively amplifying a nucleic acid using the polymerase chain reaction
10 (PCR) methods and cDNA or genomic DNA. It is possible to design synthetic oligonucleotide primers from the nucleic acid molecules as shown in SEQ ID NO:1 (Figure 6A) and SEQ ID NO:3 (Figure 7A) or a mutated sequence shown in Table 1, for use in PCR. A nucleic acid can be amplified from cDNA or genomic DNA using these oligonucleotide primers and standard PCR
15 amplification techniques. The nucleic acid so amplified can be cloned into an appropriate vector and characterized by DNA sequence analysis. It will be appreciated that cDNA may be prepared from mRNA, by isolating total cellular mRNA by a variety of techniques, for example, by using the guanidinium-thiocyanate extraction procedure of Chirgwin et al., *Biochemistry*, 18, 5294-
20 5299 (1979). cDNA is then synthesized from the mRNA using reverse transcriptase (for example, Moloney MLV reverse transcriptase available from Gibco/BRL, Bethesda, MD, or AMV reverse transcriptase available from Seikagaku America, Inc., St. Petersburg, FL).

An isolated nucleic acid molecule of the invention which is RNA can be
25 isolated by cloning a cDNA encoding a novel protein of the invention into an appropriate vector which allows for transcription of the cDNA to produce an RNA molecule which encodes the malin protein. For example, a cDNA can be cloned downstream of a bacteriophage promoter, (e.g. a T7 promoter) in a vector, cDNA can be transcribed *in vitro* with T7 polymerase, and the resultant
30 RNA can be isolated by standard techniques.

A nucleic acid molecule of the invention may also be chemically synthesized using standard techniques. Various methods of chemically

synthesizing polydeoxynucleotides are known, including solid-phase synthesis which, like peptide synthesis, has been fully automated in commercially available DNA synthesizers (See e.g., Itakura et al. U.S. Patent No. 4,598,049; Caruthers et al. U.S. Patent No. 4,458,066; and Itakura U.S. Patent Nos. 4,401,796 and 4,373,071).

The initiation codon and untranslated sequences of the nucleic acid molecules of the invention may be determined using currently available computer software designed for the purpose, such as PC/Gene (IntelliGenetics Inc., Calif.). Regulatory elements can be identified using conventional techniques. The function of the elements can be confirmed by using these elements to express a reporter gene which is operatively linked to the elements. These constructs may be introduced into cultured cells using standard procedures. In addition to identifying regulatory elements in DNA, such constructs may also be used to identify proteins interacting with the elements, using techniques known in the art.

The sequence of a nucleic acid molecule of the invention may be inverted relative to its normal presentation for transcription to produce an antisense nucleic acid molecule. Preferably, an antisense sequence is constructed by inverting a region preceding the initiation codon or an unconserved region. In particular, the nucleic acid sequences contained in the nucleic acid molecules of the invention or a fragment thereof, preferably a nucleic acid sequence shown in SEQ ID NO:1 (Figure 6A) and SEQ ID NO:3 (Figure 7A) or a mutated sequence shown in Table 1 may be inverted relative to its normal presentation for transcription to produce antisense nucleic acid molecules.

The antisense nucleic acid molecules of the invention or a fragment thereof, may be chemically synthesized using naturally occurring nucleotides or variously modified nucleotides designed to increase the biological stability of the molecules or to increase the physical stability of the duplex formed with mRNA or the native gene e.g. phosphorothioate derivatives and acridine substituted nucleotides. The antisense sequences may be produced biologically using an expression vector introduced into cells in the form of a

recombinant plasmid, phagemid or attenuated virus in which antisense sequences are produced under the control of a high efficiency regulatory region, the activity of which may be determined by the cell type into which the vector is introduced.

- 5 The invention also provides nucleic acids encoding fusion proteins comprising a novel protein of the invention and a selected protein, or a selectable marker protein (see below).

II. NOVEL PROTEINS OF THE INVENTION

- 10 The invention further includes an isolated protein encoded by the nucleic acid molecules of the invention. Within the context of the present invention, a protein of the invention may include various structural forms of the primary protein which retain biological activity.

- 15 Broadly stated, the present invention provides an isolated protein containing a zinc finger of the RING type in the N-terminal half and 6 NHL-repeat domains in the C-terminal direction which is associated with Lafora's disease. Preferably, the zinc-binding RING-finger motif (C-X₂-C-X₁₆-C-X₁-H-X₂-C-X₂-C-X₁₄-C-X₂-C) is located between residues 26-71 of the malin protein shown in Figure 6B. The presence of a RING finger is predictive of an E3 ubiquitin ligase function. Therefore, in a preferred embodiment, the protein
20 has a ubiquitin ligase function.

 In a specific embodiment of the invention, the protein has the amino acid sequence as shown in SEQ ID NO:2 (Figure 6B). In another embodiment, the protein has the amino acid sequence shown in SEQ ID NO:4 (Figure 7B).

- 25 In addition to full length amino acid sequences the proteins of the present invention also include truncations of the protein, and analogs, and homologs of the protein and truncations thereof as described herein. Truncated proteins may comprise peptides of at least fifteen amino acid residues.

- 30 Analogous of the protein having the amino acid sequence shown in SEQ ID NO:2 (Figure 6B) or SEQ ID NO:4 (Figure 7B) and/or truncations thereof as described herein, may include, but are not limited to an amino acid

sequence containing one or more amino acid substitutions, insertions, and/or deletions. Amino acid substitutions may be of a conserved or non-conserved nature. Conserved amino acid substitutions involve replacing one or more amino acids of the proteins of the invention with amino acids of similar charge, size, and/or hydrophobicity characteristics. When only conserved substitutions are made the resulting analog should be functionally equivalent. Non-conserved substitutions involve replacing one or more amino acids of the amino acid sequence with one or more amino acids which possess dissimilar charge, size, and/or hydrophobicity characteristics.

One or more amino acid insertions may be introduced into the amino acid sequences shown in SEQ ID NO:2 (Figure 6B) or SEQ ID NO:4 (Figure 7B). Amino acid insertions may consist of single amino acid residues or sequential amino acids ranging from 2 to 15 amino acids in length. For example, amino acid insertions may be used to destroy target sequences so that the protein is no longer active. This procedure may be used *in vivo* to inhibit the activity of a protein of the invention.

Deletions may consist of the removal of one or more amino acids, or discrete portions from the amino acid sequence shown in SEQ ID NO:2 (Figure 6B) or SEQ ID NO:4 (Figure 7B). The deleted amino acids may or may not be contiguous. The lower limit length of the resulting analog with a deletion mutation is about 10 amino acids, preferably 100 amino acids.

Analogues of a protein of the invention may be prepared by introducing mutations in the nucleotide sequence encoding the protein. Mutations in nucleotide sequences constructed for expression of analogues of a protein of the invention must preserve the reading frame of the coding sequences. Furthermore, the mutations will preferably not create complementary regions that could hybridize to produce secondary mRNA structures, such as loops or hairpins, which could adversely affect translation of the receptor mRNA.

Mutations may be introduced at particular loci by synthesizing oligonucleotides containing a mutant sequence, flanked by restriction sites enabling ligation to fragments of the native sequence. Following ligation, the

resulting reconstructed sequence encodes an analog having the desired amino acid insertion, substitution, or deletion.

Alternatively, oligonucleotide-directed site specific mutagenesis procedures may be employed to provide an altered gene having particular
5 codons altered according to the substitution, deletion, or insertion required. Deletion or truncation of a protein of the invention may also be constructed by utilizing convenient restriction endonuclease sites adjacent to the desired deletion. Subsequent to restriction, overhangs may be filled in, and the DNA religated. Exemplary methods of making the alterations set forth above are
10 disclosed by Sambrook et al (Molecular Cloning: A Laboratory Manual, 2nd Ed., Cold Spring Harbor Laboratory Press, 1989).

The proteins of the invention also include homologs of the amino acid sequence shown in SEQ ID NO:2 (Figure 6B) or SEQ ID NO:4 (Figure 7B) and/or truncations thereof as described herein. Such homologs are proteins
15 whose amino acid sequences are comprised of amino acid sequences that hybridize under stringent hybridization conditions (see discussion of stringent hybridization conditions herein) with a probe used to obtain a protein of the invention. Preferably, homologs of a protein of the invention will have a tyrosine phosphatase region which is characteristic of the protein.

20 A homologous protein includes a protein with an amino acid sequence having at least 70%, preferably 80-90% identity with the amino acid sequence as shown in SEQ ID NO:2 (Figure 6B) or SEQ ID NO:4 (Figure 7B).

The invention also contemplates isoforms of the proteins of the invention. An isoform contains the same number and kinds of amino acids as
25 a protein of the invention, but the isoform has a different molecular structure. The isoforms contemplated by the present invention are those having the same properties as a protein of the invention as described herein.

The invention also includes an isolated protein that has a mutation as compared to the amino acid sequence shown in SEQ ID NO:2 (Figure 6B) or
30 SEQ ID NO:4 (Figure 7B), wherein said mutation is associated with Lafora's disease. In a preferred embodiment, the mutation is selected from one of the mutations shown in Table 1.

The present invention also includes a protein of the invention conjugated with a selected protein, or a selectable marker protein (see below) to produce fusion proteins. Additionally, immunogenic portions of a protein of the invention are within the scope of the invention.

5 The proteins of the invention (including truncations, analogs, mutants etc.) may be prepared using recombinant DNA methods. Accordingly, the nucleic acid molecules of the present invention having a sequence which encodes a protein of the invention may be incorporated in a known manner into an appropriate expression vector which ensures good expression of the
10 protein. Possible expression vectors include but are not limited to cosmids, plasmids, or modified viruses (e.g. replication defective retroviruses, adenoviruses and adeno-associated viruses), so long as the vector is compatible with the host cell used. The expression vectors are "suitable for transformation of a host cell", means that the expression vectors contain a
15 nucleic acid molecule of the invention and regulatory sequences selected on the basis of the host cells to be used for expression, which is operatively linked to the nucleic acid molecule. Operatively linked is intended to mean that the nucleic acid is linked to regulatory sequences in a manner which allows expression of the nucleic acid.

20 The invention therefore contemplates a recombinant expression vector of the invention containing a nucleic acid molecule of the invention, or a fragment thereof, and the necessary regulatory sequences for the transcription and translation of the inserted protein-sequence. Suitable regulatory sequences may be derived from a variety of sources, including
25 bacterial, fungal, or viral genes (For example, see the regulatory sequences described in Goeddel, Gene Expression Technology: Methods in Enzymology 185, Academic Press, San Diego, CA (1990). Selection of appropriate regulatory sequences is dependent on the host cell chosen, and may be readily accomplished by one of ordinary skill in the art. Examples of such
30 regulatory sequences include: a transcriptional promoter and enhancer or RNA polymerase binding sequence, a ribosomal binding sequence, including a translation initiation signal. Additionally, depending on the host cell chosen

and the vector employed, other sequences, such as an origin of replication, additional DNA restriction sites, enhancers, and sequences conferring inducibility of transcription may be incorporated into the expression vector. It will also be appreciated that the necessary regulatory sequences may be
5 supplied by the native protein and/or its flanking regions.

The invention further provides a recombinant expression vector comprising a DNA nucleic acid molecule of the invention cloned into the expression vector in an antisense orientation. That is, the DNA molecule is operatively linked to a regulatory sequence in a manner which allows for
10 expression, by transcription of the DNA molecule, of an RNA molecule which is antisense to a nucleotide sequence comprising the nucleotides as shown SEQ ID NO:1 or SEQ ID NO:3. Regulatory sequences operatively linked to the antisense nucleic acid can be chosen which direct the continuous expression of the antisense RNA molecule.

15 The recombinant expression vectors of the invention may also contain a selectable marker gene which facilitates the selection of host cells transformed or transfected with a recombinant molecule of the invention. Examples of selectable marker genes are genes encoding a protein such as G418 and hygromycin which confer resistance to certain drugs, β -galactosidase, chloramphenicol acetyltransferase, or firefly luciferase.
20 Transcription of the selectable marker gene is monitored by changes in the concentration of the selectable marker protein such as β -galactosidase, chloramphenicol acetyltransferase, or firefly luciferase. If the selectable marker gene encodes a protein conferring antibiotic resistance such as
25 neomycin resistance transformant cells can be selected with G418. Cells that have incorporated the selectable marker gene will survive, while the other cells die. This makes it possible to visualize and assay for expression of recombinant expression vectors of the invention and in particular to determine the effect of a mutation on expression and phenotype. It will be appreciated
30 that selectable markers can be introduced on a separate vector from the nucleic acid of interest.

The recombinant expression vectors may also contain genes which encode a fusion moiety which provides increased expression of the recombinant protein; increased solubility of the recombinant protein; and aid in the purification of a target recombinant protein by acting as a ligand in affinity purification. For example, a proteolytic cleavage site may be added to the target recombinant protein to allow separation of the recombinant protein from the fusion moiety subsequent to purification of the fusion protein.

Recombinant expression vectors can be introduced into host cells to produce a transformed host cell. The term "transformed host cell" is intended to include prokaryotic and eukaryotic cells which have been transformed or transfected with a recombinant expression vector of the invention. The terms "transformed with", "transfected with", "transformation" and "transfection" are intended to encompass introduction of nucleic acid (e.g. a vector) into a cell by one of many possible techniques known in the art. Prokaryotic cells can be transformed with nucleic acid by, for example, electroporation or calcium-chloride mediated transformation. Nucleic acid can be introduced into mammalian cells via conventional techniques such as calcium phosphate or calcium chloride co precipitation, DEAE-dextran-mediated transfection, lipofectin, electroporation or microinjection. Suitable methods for transforming and transfecting host cells can be found in Sambrook et al. (Molecular Cloning: A Laboratory Manual, 2nd Edition, Cold Spring Harbor Laboratory press (1989)), and other laboratory textbooks.

Suitable host cells include a wide variety of prokaryotic and eukaryotic host cells. For example, the proteins of the invention may be expressed in bacterial cells such as *E. coli*, insect cells (using baculovirus), yeast cells or mammalian cells. Other suitable host cells can be found in Goeddel, Gene Expression Technology: Methods in Enzymology 185, Academic Press, San Diego, CA (1991).

The proteins of the invention may also be prepared by chemical synthesis using techniques well known in the chemistry of proteins such as solid phase synthesis (Merrifield, 1964, J. Am. Chem. Assoc. 85:2149-

2154) or synthesis in homogenous solution (Houbenweyl, 1987, Methods of Organic Chemistry, ed. E. Wansch, Vol. 15 I and II, Thieme, Stuttgart).

III. APPLICATIONS

The present invention includes all uses of the nucleic acid molecule
5 and proteins of the invention including, but not limited to, the preparation of antibodies and antisense oligonucleotides, the preparation of experimental systems to study *EPM2B* and mutated forms thereof, the isolation of substances that modulate *EPM2B* expression and/or activity as well as the use of the *EPM2B* nucleic acid sequences and proteins and modulators
10 thereof in diagnostic and therapeutic applications. Some of the uses are further described below.

A. Diagnostic Applications

As previously mentioned, the present inventors have determined that the gene *EPM2B* is mutated in people with Lafora's disease. As a result, the
15 present invention also includes a method of detecting Lafora's disease by detecting a mutation in the *EPM2B* gene or protein.

(i) Detecting Mutations in the Nucleic Acid Sequence

In one embodiment, the present invention provides a method for detecting Lafora's disease comprising detecting a mutation in the *EPM2B*
20 gene in a sample obtained from an animal, preferably a mammal, more preferably a human.

Table 1 summarizes some of the mutations found in *EPM2B* in patients with Lafora's disease. To date, 17 different DNA sequence alterations have been found in *EPM2B* in 26 families including 8 deletions and 1 insertion
25 leading to frame-shifts, 7 missense, and 1 non-sense change. Screening assays can be developed for each of the mutations.

The most common mutation identified in seven families is a homozygous 205C → G transition resulting in a proline to alanine change in the RING-finger domain. Accordingly, in one embodiment, the present
30 invention provides a method of detecting Lafora's disease comprising detecting a C → G mutation at position 205 in the *EPM2B* gene (SEQ ID NO:1).

Another mutation observed in the four consanguineous F-C families used in the original linkage study all carried a homozygous 76T>A change producing a cysteine-to-serine alteration in one of the 7 conserved cysteine residues that are critical for the zinc-binding ability of the RING-finger domain.

- 5 Accordingly, in another embodiment, the present invention provides a method of detecting Lafora's disease comprising detecting a T → A mutation at position 76 in the *EPM2B* gene (SEQ ID NO:1).

Another mutation was observed in the LD38324 family that was critical in refining the *EPM2B* locus (Figure 2a) which was a homozygous 2-bp
10 deletion (1048-1049delGA) leading to a frame-shift mutation in the fifth NHL-domain (Figure 2b). Accordingly, in a further embodiment, the present invention provides a method of detecting Lafora's disease comprising detecting a deletion of GA at positions 1048 and 1049 in the *EPM2B* gene (SEQ ID NO:1).

- 15 One skilled in the art will appreciate that other methods, in addition to the ones discussed above and in the examples, can be used to detect mutations in the *EPM2B* gene. For example, in order to isolate nucleic acids from the Lafora's disease gene in a sample, one can prepare nucleotide probes from the nucleic acid sequences of the invention. In addition, the
20 nucleic acid probes described herein can also be used. A nucleotide probe may be labelled with a detectable marker such as a radioactive label which provides for an adequate signal and has sufficient half life such as ³²P, ³H, ¹⁴C or the like. Other detectable markers which may be used include antigens that are recognized by a specific labelled antibody, fluorescent compounds,
25 enzymes, antibodies specific for a labelled antigen, and chemiluminescent compounds. An appropriate label may be selected having regard to the rate of hybridization and binding of the probe to the nucleotide to be detected and the amount of nucleotide available for hybridization.

- Accordingly, the present invention also relates to a method of detecting
30 the presence of a nucleic acid molecule from the *EPM2B* gene in a sample comprising contacting the sample under hybridization conditions with one or more of nucleotide probes which hybridize to the nucleic acid molecules and

are labelled with a detectable marker, and determining the degree of hybridization between the nucleic acid molecule in the sample and the nucleotide probes.

Hybridization conditions which may be used in the methods of the invention are known in the art and are described for example in Sambrook J, Fritsch EF, Maniatis T. In: Molecular Cloning, A Laboratory Manual, 1989. (Nolan C, Ed.), Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY. The hybridization product may be assayed using techniques known in the art. The nucleotide probe may be labelled with a detectable marker as described herein and the hybridization product may be assayed by detecting the detectable marker or the detectable change produced by the detectable marker.

Prior to hybridizing a sample with DNA probes, the sample can be treated with primers that flank the *EPM2B* gene in order to amplify the nucleic acid sequences in the sample. The primers used may be the ones described in the present application. In addition, the sequence of the *EPM2B* gene provided herein also permits the identification and isolation, or synthesis of new nucleotide sequences which may be used as primers to amplify a nucleic acid molecule of the invention, for example in the polymerase chain reaction (PCR) which is discussed in more detail below. The primers may be used to amplify the genomic DNA of other species. The PCR amplified sequences can be examined to determine the relationship between the genes of various species.

The length and bases of the primers for use in the PCR are selected so that they will hybridize to different strands of the desired sequence and at relative positions along the sequence such that an extension product synthesized from one primer when it is separated from its template can serve as a template for extension of the other primer into a nucleic acid of defined length. Primers which may be used in the invention are oligonucleotides i.e. molecules containing two or more deoxyribonucleotides of the nucleic acid molecule of the invention which occur naturally as in a purified restriction endonuclease digest or are produced synthetically using techniques known in

the art such as for example phosphotriester and phosphodiester methods (See Good et al Nucl. Acid Res 4:2157, 1977) or automated techniques (See for example, Conolly, B .A. Nucleic Acids Res. 15:15(7): 3131, 1987). The primers are capable of acting as a point of initiation of synthesis when placed
5 under conditions which permit the synthesis of a primer extension product which is complementary to the DNA sequence of the invention i.e. in the presence of nucleotide substrates, an agent for polymerization such as DNA polymerase and at suitable temperature and pH. Preferably, the primers are sequences that do not form secondary structures by base pairing with other
10 copies of the primer or sequences that form a hair pin configuration. The primer preferably contains between about 7 and 25 nucleotides.

The primers may be labelled with detectable markers which allow for detection of the amplified products. Suitable detectable markers are radioactive markers such as P-32, S-35, I-125, and H-3, luminescent markers
15 such as chemiluminescent markers, preferably luminol, and fluorescent markers, preferably dansyl chloride, fluorcein-5-isothiocyanate, and 4-fluor-7-nitrobenz-2-axa-1,3 diazole, enzyme markers such as horseradish peroxidase, alkaline phosphatase, β -galactosidase, acetylcholinesterase, or biotin.

20 It will be appreciated that the primers may contain non-complementary sequences provided that a sufficient amount of the primer contains a sequence which is complementary to a nucleic acid molecule of the invention or oligonucleotide fragment thereof, which is to be amplified. Restriction site linkers may also be incorporated into the primers allowing for digestion of the
25 amplified products with the appropriate restriction enzymes facilitating cloning and sequencing of the amplified product.

In an embodiment of the invention a method of determining the presence of a nucleic acid molecule of the invention is provided comprising treating the sample with primers which are capable of amplifying the nucleic
30 acid molecule or a predetermined oligonucleotide fragment thereof in a polymerase chain reaction to form amplified sequences, under conditions

which permit the formation of amplified sequences and, assaying for amplified sequences.

The polymerase chain reaction refers to a process for amplifying a target nucleic acid sequence as generally described in Innis et al, Academic Press, 1990 in Mullis et al., U.S. Pat. No. 4,863,195 and Mullis, U.S. Patent No. 4,683,202 which are incorporated herein by reference. Conditions for amplifying a nucleic acid template are described in M.A. Innis and D.H. Gelfand, PCR Protocols, A Guide to Methods and Applications M.A. Innis, D.H. Gelfand, J.J. Sninsky and T.J. White eds, pp3-12, Academic Press 1989, which is also incorporated herein by reference.

The amplified products can be isolated and distinguished based on their respective sizes using techniques known in the art. For example, after amplification, the DNA sample can be separated on an agarose gel and visualized, after staining with ethidium bromide, under ultra violet (UV) light. DNA may be amplified to a desired level and a further extension reaction may be performed to incorporate nucleotide derivatives having detectable markers such as radioactive labelled or biotin labelled nucleoside triphosphates. The primers may also be labelled with detectable markers as discussed above. The detectable markers may be analyzed by restriction and electrophoretic separation or other techniques known in the art.

The conditions which may be employed in the methods of the invention using PCR are those which permit hybridization and amplification reactions to proceed in the presence of DNA in a sample and appropriate complementary hybridization primers. Conditions suitable for the polymerase chain reaction are generally known in the art. For example, see M.A. Innis and D.H. Gelfand, PCR Protocols, A guide to Methods and Applications M.A. Innis, D.H. Gelfand, J.J. Sninsky and T.J. White eds, pp3-12, Academic Press 1989, which is incorporated herein by reference. Preferably, the PCR utilizes polymerase obtained from the thermophilic bacterium *Thermus aquaticus* (Taq polymerase, GeneAmp Kit, Perkin Elmer Cetus) or other thermostable polymerase may be used to amplify DNA template strands.

It will be appreciated that other techniques such as the Ligase Chain Reaction (LCR) and NASBA may be used to amplify a nucleic acid molecule of the invention (Barney in "PCR Methods and Applications", August 1991, Vol.1(1), page 5, and European Published Application No. 0320308, published June 14, 1989, and U.S. Serial NO. 5,130,238 to Malek).

(ii) Detecting the Malin Protein

In another embodiment, the present invention provides a method for detecting Lafora's disease comprising determining if the malin protein is present or mutated in a sample from a mammal, preferably a human, suspected of having Lafora's disease.

The malin protein of the present invention may be detected in a biological sample using antibodies that are specific for malin using various immunoassays that are discussed below. Antibodies that only react with mutated malin would be useful as diagnostic agents to detect Lafora's disease. As such, antibodies would be prepared that bind only a mutated region of the protein.

Conventional methods can be used to prepare the antibodies. For example, by using a peptide from the malin protein of the invention, polyclonal antisera or monoclonal antibodies can be made using standard methods. A mammal, (e.g., a mouse, hamster, or rabbit) can be immunized with an immunogenic form of the peptide which elicits an antibody response in the mammal. Techniques for conferring immunogenicity on a peptide include conjugation to carriers or other techniques well known in the art. For example, the peptide can be administered in the presence of adjuvant. The progress of immunization can be monitored by detection of antibody titers in plasma or serum. Standard ELISA or other immunoassay procedures can be used with the immunogen as antigen to assess the levels of antibodies. Following immunization, antisera can be obtained and, if desired, polyclonal antibodies isolated from the sera.

To produce monoclonal antibodies, antibody producing cells (lymphocytes) can be harvested from an immunized animal and fused with myeloma cells by standard somatic cell fusion procedures thus immortalizing

these cells and yielding hybridoma cells. Such techniques are well known in the art, (e.g., the hybridoma technique originally developed by Kohler and Milstein (Nature 256, 495-497 (1975)) as well as other techniques such as the human B-cell hybridoma technique (Kozbor et al., Immunol. Today 4, 72
5 (1983)), the EBV hybridoma technique to produce human monoclonal antibodies (Cole et al. Monoclonal Antibodies in Cancer Therapy (1985) Allen R. Bliss, Inc., pages 77-96), and screening of combinatorial antibody libraries (Huse et al., Science 246, 1275 (1989)). Hybridoma cells can be screened
10 immunochemically for production of antibodies specifically reactive with the peptide and the monoclonal antibodies can be isolated. Therefore, the invention also contemplates hybridoma cells secreting monoclonal antibodies with specificity for a protein of the invention.

The term "antibody" as used herein is intended to include fragments thereof which also specifically react with a protein, of the invention, or peptide
15 thereof. Antibodies can be fragmented using conventional techniques and the fragments screened for utility in the same manner as described above. For example, F(ab')₂ fragments can be generated by treating antibody with pepsin. The resulting F(ab')₂ fragment can be treated to reduce disulfide bridges to produce Fab' fragments.

20 Chimeric antibody derivatives, i.e., antibody molecules that combine a non human animal variable region and a human constant region are also contemplated within the scope of the invention. Chimeric antibody molecules can include, for example, the antigen binding domain from an antibody of a mouse, rat, or other species, with human constant regions. Conventional
25 methods may be used to make chimeric antibodies containing the immunoglobulin variable region which recognizes a malin protein (see, for example, Morrison et al., Proc. Natl Acad. Sci. U.S.A. 81,6851 (1985); Takeda et al., Nature 314, 452 (1985), Cabilly et al., U.S. Patent No. 4,816,567; Boss et al., U.S. Patent No. 4,816,397; Tanaguchi et al.,
30 European Patent Publication EP171496; European Patent Publication 0173494, United Kingdom patent GB 2177096B).

Monoclonal or chimeric antibodies specifically reactive with a protein of the invention as described herein can be further humanized by producing human constant region chimeras, in which parts of the variable regions, particularly the conserved framework regions of the antigen-binding domain, are of human origin and only the hypervariable regions are of non-human origin. Such immunoglobulin molecules may be made by techniques known in the art, (e.g., Teng et al., Proc. Natl. Acad. Sci. U.S.A., 80, 7308-7312 (1983); Kozbor et al., Immunology Today, 4, 7279 (1983); Olsson et al., Meth. Enzymol., 92, 3-16 (1982)), and PCT Publication WO92/06193 or EP 0239400). Humanized antibodies can also be commercially produced (Scotgen Limited, 2 Holly Road, Twickenham, Middlesex, Great Britain.)

Specific antibodies, or antibody fragments, reactive against a protein of the invention may also be generated by screening expression libraries encoding immunoglobulin genes, or portions thereof, expressed in bacteria with peptides produced from the nucleic acid molecules of the present invention. For example, complete Fab fragments, VH regions and FV regions can be expressed in bacteria using phage expression libraries (See for example Ward et al., Nature 341, 544-546: (1989); Huse et al., Science 246, 1275-1281 (1989); and McCafferty et al. Nature 348, 552-554 (1990)).

Antibodies may also be prepared using DNA immunization. For example, an expression vector containing a nucleic acid of the invention (as described above) may be injected into a suitable animal such as mouse. The protein of the invention will therefore be expressed *in vivo* and antibodies will be induced. The antibodies can be isolated and prepared as described above for protein immunization.

The antibodies may be labelled with a detectable marker including various enzymes, fluorescent materials, luminescent materials and radioactive materials. Examples of suitable enzymes include horseradish peroxidase, biotin, alkaline phosphatase, β -galactosidase, or acetylcholinesterase; examples of suitable fluorescent materials include umbelliferone, fluorescein, fluorescein isothiocyanate, rhodamine, dichlorotriazinylamine fluorescein, dansyl chloride or phycoerythrin; an example of a luminescent material

includes luminol; and examples of suitable radioactive material include S-35, Cu-64, Ga-67, Zr-89, Ru-97, Tc-99m, Rh-105, Pd-109, In-111, I-123, I-125, I131, Re-186, Au-198, Au-199, Pb-203, At-211, Pb-212 and Bi-212. The antibodies may also be labelled or conjugated to one partner of a ligand binding pair. Representative examples include avidin-biotin and riboflavin-riboflavin binding protein. Methods for conjugating or labelling the antibodies discussed above with the representative labels set forth above may be readily accomplished using conventional techniques.

The antibodies reactive against proteins of the invention (e.g. enzyme conjugates or labelled derivatives) may be used to detect a protein of the invention in various samples, for example they may be used in any known immunoassays which rely on the binding interaction between an antigenic determinant of a protein of the invention and the antibodies. Examples of such assays are radioimmunoassays, enzyme immunoassays (e.g. ELISA), immunofluorescence, immuno-precipitation, latex agglutination, hemagglutination, and histochemical tests. Thus, the antibodies may be used to identify or quantify the amount of a protein of the invention in a sample in order to diagnose the presence of Lafora's disease.

In a method of the invention a predetermined amount of a sample or concentrated sample is mixed with antibody or labelled antibody. The amount of antibody used in the process is dependent upon the labelling agent chosen. The resulting protein bound to antibody or labelled antibody may be isolated by conventional isolation techniques, for example, salting out, chromatography, electrophoresis, gel filtration, fractionation, absorption, polyacrylamide gel electrophoresis, agglutination, or combinations thereof.

The sample or antibody may be insolubilized, for example, the sample or antibody can be reacted using known methods with a suitable carrier. Examples of suitable carriers are Sepharose or agarose beads. When an insolubilized sample or antibody is used protein bound to antibody or unreacted antibody is isolated by washing. For example, when the sample is blotted onto a nitrocellulose membrane, the antibody bound to a protein of the invention is separated from the unreacted antibody by washing with a buffer,

for example, phosphate buffered saline (PBS) with bovine serum albumin (BSA).

When labelled antibody is used, the presence of malin can be determined by measuring the amount of labelled antibody bound to a protein of the invention in the sample or of the unreacted labelled antibody. The appropriate method of measuring the labelled material is dependent upon the labelling agent.

When unlabelled antibody is used in the method of the invention, the presence of malin can be determined by measuring the amount of antibody bound to the protein using substances that interact specifically with the antibody to cause agglutination or precipitation. In particular, labelled antibody against an antibody specific for a protein of the invention, can be added to the reaction mixture. The presence of a protein of the invention can be determined by a suitable method from among the already described techniques depending on the type of labelling agent. The antibody against an antibody specific for a protein of the invention can be prepared and labelled by conventional procedures known in the art which have been described herein. The antibody against an antibody specific for a protein of the invention may be a species specific anti-immunoglobulin antibody or monoclonal antibody, for example, goat anti-rabbit antibody may be used to detect rabbit antibody specific for a protein of the invention.

(iii) Kits

The reagents suitable for carrying out the methods of the invention may be packaged into convenient kits providing the necessary materials, packaged into suitable containers. Such kits may include all the reagents required to detect a nucleic acid molecule or protein of the invention in a sample by means of the methods described herein, and optionally suitable supports useful in performing the methods of the invention.

In one embodiment of the invention, the kit includes primers which are capable of amplifying a nucleic acid molecule of the invention or a predetermined oligonucleotide fragment thereof, all the reagents required to produce the amplified nucleic acid molecule or predetermined fragment

thereof in the polymerase chain reaction, and means for assaying the amplified sequences. The kit may also include restriction enzymes to digest the PCR products. In another embodiment of the invention the kit contains a nucleotide probe which hybridizes with a nucleic acid molecule of the invention, reagents required for hybridization of the nucleotide probe with the nucleic acid molecule, and directions for its use. In a further embodiment of the invention the kit includes antibodies of the invention and reagents required for binding of the antibody to a protein of the invention in a sample.

The methods and kits of the present invention may be used to detect Lafora's disease. Samples which may be tested include bodily materials such as blood, urine, serum, tears, saliva, feces, tissues, cells and the like. In addition to human samples, samples may be taken from mammals such as non-human primates, etc.

Before testing a sample in accordance with the methods described herein, the sample may be concentrated using techniques known in the art, such as centrifugation and filtration. For the hybridization and/or PCR-based methods described herein, nucleic acids may be extracted from cell extracts of the test sample using techniques known in the art.

B. *EPM2B*/Malin Modulators

In addition to antibodies and antisense oligonucleotides described above, other substances that modulate *EPM2B* expression or activity may also be identified, as well as substances that modulate mutated forms of malin.

(i) Substances that Bind Malin

Substances that affect malin activity can be identified based on their ability to bind to malin and/or mutated malin.

Substances which can bind with the malin of the invention may be identified by reacting the malin with a substance which potentially binds to malin, and assaying for complexes, for free substance, or for non-complexed malin, or for activation of malin. In particular, a yeast two hybrid assay system may be used to identify proteins which interact with malin (Fields, S. and

Song, O., 1989, Nature, 340:245-247). Systems of analysis which also may be used include ELISA.

Accordingly, the invention provides a method of identifying substances which can bind with malin, comprising the steps of:

5 (a) reacting malin and a test substance, under conditions which allow for formation of a complex between the malin and the test substance, and

 (b) assaying for complexes of malin and the test substance, for free substance or for non complexed malin, wherein the presence of complexes
10 indicates that the test substance is capable of binding malin.

The malin protein used in the assay may have the amino acid sequence shown in SEQ ID NO:2 (Figure 6B) or SEQ ID NO:4 (Figure 7B) or may be a mutated protein as shown in Table 1 or may be a fragment, analog, derivative, homolog or mimetic thereof as described herein.

15 Conditions which permit the formation of substance and malin complexes may be selected having regard to factors such as the nature and amounts of the substance and the protein.

The substance-protein complex, free substance or non-complexed proteins may be isolated by conventional isolation techniques, for example,
20 salting out, chromatography, electrophoresis, gel filtration, fractionation, absorption, polyacrylamide gel electrophoresis, agglutination, or combinations thereof. To facilitate the assay of the components, antibody against malin or the substance, or labelled malin, or a labelled substance may be utilized. The antibodies, proteins, or substances may be labelled with a detectable
25 substance as described above.

Malin, or the substance used in the method of the invention may be insolubilized. For example, malin or substance may be bound to a suitable carrier. Examples of suitable carriers are agarose, cellulose, dextran, Sephadex, Sepharose, carboxymethyl cellulose polystyrene, filter paper, ion-
30 exchange resin, plastic film, plastic tube, glass beads, polyamine-methyl vinyl-ether-maleic acid copolymer, amino acid copolymer, ethylene-maleic acid

copolymer, nylon, silk, etc. The carrier may be in the shape of, for example, a tube, test plate, beads, disc, sphere etc.

The insolubilized protein or substance may be prepared by reacting the material with a suitable insoluble carrier using known chemical or physical
5 methods, for example, cyanogen bromide coupling.

The proteins or substance may also be expressed on the surface of a cell using the methods described herein.

The invention also contemplates assaying for an antagonist or agonist of the action of malin.

10 It will be understood that the agonists and antagonists that can be assayed using the methods of the invention may act on one or more of the binding sites on the protein or substance including agonist binding sites, competitive antagonist binding sites, non-competitive antagonist binding sites or allosteric sites.

15 The invention also makes it possible to screen for antagonists that inhibit the effects of an agonist of malin. Thus, the invention may be used to assay for a substance that competes for the same binding site of malin.

(ii) Peptide Mimetics

The present invention also includes peptide mimetics of the malin and
20 mutated malin proteins of the invention. For example, a peptide derived from a the mutated domain of malin will interact directly or indirectly with an associated molecule in such a way as to mimic the native binding of the mutated protein. Such peptides may include competitive inhibitors, enhancers, peptide mimetics, and the like. All of these peptides as well as
25 molecules substantially homologous, complementary or otherwise functionally or structurally equivalent to these peptides may be used for purposes of the present invention.

"Peptide mimetics" are structures which serve as substitutes for peptides in interactions between molecules (See Morgan et al (1989), Ann.
30 Reports Med. Chem. 24:243-252 for a review). Peptide mimetics include synthetic structures which may or may not contain amino acids and/or peptide bonds but retain the structural and functional features of a peptide, or

enhancer or inhibitor of the invention. Peptide mimetics also include peptoids, oligopeptoids (Simon et al (1972) Proc. Natl. Acad, Sci USA 89:9367); and peptide libraries containing peptides of a designed length representing all possible sequences of amino acids corresponding to a peptide of the
5 invention.

Peptide mimetics may be designed based on information obtained by systematic replacement of L-amino acids by D-amino acids, replacement of side chains with groups having different electronic properties, and by systematic replacement of peptide bonds with amide bond replacements.
10 Local conformational constraints can also be introduced to determine conformational requirements for activity of a candidate peptide mimetic. The mimetics may include isosteric amide bonds, or D-amino acids to stabilize or promote reverse turn conformations and to help stabilize the molecule. Cyclic amino acid analogues may be used to constrain amino acid residues to
15 particular conformational states. The mimetics can also include mimics of inhibitor peptide secondary structures. These structures can model the 3-dimensional orientation of amino acid residues into the known secondary conformations of proteins. Peptoids may also be used which are oligomers of N-substituted amino acids and can be used as motifs for the generation of
20 chemically diverse libraries of novel molecules.

Peptides of the invention may also be used to identify lead compounds for drug development. The structure of the peptides described herein can be readily determined by a number of methods such as NMR and X-ray crystallography. A comparison of the structures of peptides similar in
25 sequence, but differing in the biological activities they elicit in target molecules can provide information about the structure-activity relationship of the target. Information obtained from the examination of structure-activity relationships can be used to design either modified peptides, or other small molecules or lead compounds that can be tested for predicted properties as related to the
30 target molecule. The activity of the lead compounds can be evaluated using assays similar to those described herein.

Information about structure-activity relationships may also be obtained from co-crystallization studies. In these studies, a peptide with a desired activity is crystallized in association with a target molecule, and the X-ray structure of the complex is determined. The structure can then be compared
5 to the structure of the target molecule in its native state, and information from such a comparison may be used to design compounds expected to possess.

(iii) Drug Screening Methods

In accordance with one embodiment, the invention enables a method for screening candidate compounds for their ability to increase or decrease
10 the activity of the mutated malin protein. The method comprises providing an assay system for assaying malin activity, assaying the activity in the presence or absence of the candidate or test compound and determining whether the compound has increased or decreased malin activity. Such compounds may be useful in treating Lafora's disease.

15 Accordingly, the present invention provides a method for identifying a compound that affects mutated malin protein activity or expression comprising:

(a) incubating a test compound with a malin protein or a nucleic acid encoding a malin protein; and

20 (b) determining an amount of malin protein activity or expression and comparing with a control (i.e. in the absence of the test substance), wherein a change in the malin protein activity or expression as compared to the control indicates that the test compound has an effect on malin protein activity or expression.

25 In accordance with a further embodiment, the invention enables a method for screening candidate compounds for their ability to increase or decrease expression of a malin protein. The method comprises putting a cell with a candidate compound, wherein the cell includes a regulatory region of a malin gene operably joined to a reporter gene coding region, and detecting a
30 change in expression of the reporter gene.

In one embodiment, the present invention enables culture systems in which cell lines which express the mutated malin gene are incubated with

candidate compounds to test their effects on mutated malin expression. Such culture systems can be used to identify compounds which upregulate or downregulate malin expression or its function, through the interaction with other proteins.

5 Such compounds can be selected from protein compounds, chemicals and various drugs that are added to the culture medium. After a period of incubation in the presence of a selected test compound(s), the expression of mutated malin can be examined by quantifying the levels of malin mRNA using standard Northern blotting procedure, as described in the examples
10 included herein, to determine any changes in expression as a result of the test compound. Cell lines transfected with constructs expressing malin can also be used to test the function of compounds developed to modify the protein expression.

C. Therapeutic Uses

15 As previously discussed, the *EPM2B* gene and malin of the invention is likely involved in Lafora's disease. Accordingly, the present invention provides a method of treating Lafora's disease comprising of administering to a cell or animal in need thereof, an effective amount of agent that modulates *EPM2B*/malin expression and/or activity. The present invention also provides
20 a use of an agent that modulates *EPM2B*/malin expression and/or activity to treat Lafora's disease or to prepare a medicament to treat Lafora's disease.

 The term "agent that modulates *EPM2B*/malin expression and/or activity" means any substance that can alter the expression and/or activity of the mutated *EPM2B*/malin found in the patient to be consistent with the wild
25 type *EPM2B*/malin. Examples of agents which may be used to include administering: a nucleic acid molecule encoding wild type *EPM2B*; the wild type malin protein as well as fragments, analogs, derivatives or homologs thereof; antibodies; antisense nucleic acids; peptide mimetics; and substances isolated using the screening methods described herein that can
30 correct the mutation to result in *EPM2B*/malin levels and/or function consistent with a person without the disease.

The term "effective amount" as used herein means an amount effective, at dosages and for periods of time necessary to achieve the desired results.

The term "animal" as used herein includes all members of the animal
5 kingdom, including humans.

In one embodiment, the invention provides a method of treating Lafora's disease by administering to a cell or animal an effective amount of an agent that modulates the expression or the biological activity of the mutated malin protein. The present invention also provides a use of an effective
10 amount of an agent that modulates the expression or the biological activity of the mutated malin protein to treat Lafora's disease or to prepare a medicament to treat Lafora's disease. Substances that inhibit the activity of mutated malin include peptide mimetics, malin antagonists and certain antibodies to malin. Substances that inhibit the expression of the mutated
15 *EPM2B* gene include antisense oligonucleotides to a mutated *EPM2B* nucleic acid sequence.

In accordance with another embodiment, the present invention enables gene therapy as a potential therapeutic approach to Lafora's disease, in which normal copies of the *EPM2B* gene are introduced into patients to successfully
20 code for normal malin protein in several different affected cell types.

Retroviral vectors can be used for somatic cell gene therapy especially because of their high efficiency of infection and stable integration and expression. The targeted cells however must be able to divide and the expression of the levels of normal protein should be high. The full length
25 normal *EPM2B* gene can be cloned into a retroviral vector and driven from its endogenous promoter or from the retroviral long terminal repeat or from a promoter specific for the target cell type of interest. Other viral vectors which can be used include adeno-associated virus, vaccinia virus, bovine papilloma virus, or a herpesvirus such as Epstein-Barr virus. Gene transfer could also
30 be achieved using non-viral means requiring infection *in vitro*. This would include calcium phosphate, DEAE dextran, electroporation, cationic or anionic

lipid formulations (liposomes) and protoplast fusion. Although these methods are available, many of these are lower efficiency.

Anti-sense based strategies can be employed to inhibit mutated *EPM2B* gene function and as a basis for therapeutic drug design. The principle is based on the hypothesis that sequence specific suppression of gene expression can be achieved by intracellular hybridization between mRNA and a complementary anti-sense species. It is possible to synthesize anti-sense strand nucleotides that bind the sense strand of RNA or DNA with a high degree of specificity. The formation of a hybrid RNA duplex may interfere with the processing/transport/translation and/or stability of a target mRNA.

Hybridization is required for an antisense effect to occur. Antisense effects have been described using a variety of approaches including the use of antisense oligonucleotides, injection of antisense RNA, DNA and transfection of antisense RNA expression vectors.

Therapeutic antisense nucleotides can be made as oligonucleotides or expressed nucleotides. Oligonucleotides are short single strands of DNA which are usually 15 to 20 nucleic acid bases long. Expressed nucleotides are made by an expression vector such as an adenoviral, retroviral or plasmid vector. The vector is administered to the cells in culture, or to a patient, whose cells then make the antisense nucleotide. Expression vectors can be designed to produce antisense RNA, which can vary in length from a few dozen bases to several thousand.

Antisense effects can be induced by control (sense) sequences. The extent of phenotypic changes are highly variable. Phenotypic effects induced by antisense are based on changes in criteria such as biological endpoints, protein levels, protein activation measurement and target mRNA levels.

D. Pharmaceutical Compositions

The above described substances including nucleic acids encoding *EPM2B* and mutated *EPM2B*, malin and mutated malin proteins, antibodies, and antisense oligonucleotides as well as other agents that modulate *EPM2B*/malin and/or mutated *EPM2B*/malin may be formulated into

pharmaceutical compositions for administration to subjects in a biologically compatible form suitable for administration *in vivo*. By "biologically compatible form suitable for administration *in vivo*" is meant a form of the substance to be administered in which any toxic effects are outweighed by the therapeutic effects. The substances may be administered to living organisms including humans, and animals.

Administration of a therapeutically active amount of pharmaceutical compositions of the present invention is defined as an amount effective, at dosages and for periods of time necessary to achieve the desired result. For example, a therapeutically active amount of a substance may vary according to factors such as the disease state, age, sex, and weight of the individual, and the ability of the substance to elicit a desired response in the individual. Dosage regimes may be adjusted to provide the optimum therapeutic response. For example, several divided doses may be administered daily or the dose may be proportionally reduced as indicated by the exigencies of the therapeutic situation.

An active substance may be administered in a convenient manner such as by injection (subcutaneous, intravenous, etc.), oral administration, inhalation, transdermal application, or rectal administration. Depending on the route of administration, the active substance may be coated in a material to protect the compound from the action of enzymes, acids and other natural conditions which may inactivate the compound. If the active substance is a nucleic acid encoding, for example, a modified *EPM2B* gene may be delivered using techniques known in the art.

The compositions described herein can be prepared by per se known methods for the preparation of pharmaceutically acceptable compositions which can be administered to subjects, such that an effective quantity of the active substance is combined in a mixture with a pharmaceutically acceptable vehicle. Suitable vehicles are described, for example, in Remington's Pharmaceutical Sciences (Remington's Pharmaceutical Sciences, Mack Publishing Company, Easton, Pa., USA 1985) or Handbook of Pharmaceutical Additives (compiled by Michael and Irene Ash, Gower

Publishing Limited, Aldershot, England (1995)). On this basis, the compositions include, albeit not exclusively, solutions of the substances in association with one or more pharmaceutically acceptable vehicles or diluents, and may be contained in buffered solutions with a suitable pH and/or
5 be iso-osmotic with physiological fluids. In this regard, reference can be made to U.S. Patent No. 5,843,456. As will also be appreciated by those skilled, administration of substances described herein may be by an inactive viral carrier.

E. Experimental Models

10 The present invention also includes methods and experimental models for studying the function of the *EPM2B* gene and malin protein. Cells, tissues and non-human animals that lack the *EPM2B* gene or partially lack in malin expression may be developed using recombinant expression vectors having a specific deletion or mutation in the *EPM2B* gene. A recombinant expression
15 vector may be used to inactivate or alter the *EPM2B* gene by homologous recombination and thereby create an *EPM2B* deficient cell, tissue or animal.

Null alleles may be generated in cells, such as embryonic stem cells by deletion mutation. A recombinant *EPM2B* gene may also be engineered to contain an insertion mutation which inactivates *EPM2B*. Such a construct
20 may then be introduced into a cell, such as an embryonic stem cell, by a technique such as transfection, electroporation, injection etc. Cells lacking an intact *EPM2B* gene may then be identified, for example by Southern blotting, Northern Blotting or by assaying for *EPM2B* using the methods described herein. Such cells may then be fused to embryonic stem cells to generate
25 transgenic non-human animals deficient in *EPM2B*. Germline transmission of the mutation may be achieved, for example, by aggregating the embryonic stem cells with early stage embryos, such as 8 cell embryos, *in vitro*; transferring the resulting blastocysts into recipient females and; generating germline transmission of the resulting aggregation chimeras. Such a mutant
30 animal may be used to define specific cell populations, developmental patterns and *in vivo* processes, normally dependent on *EPM2B* expression.

The present invention also includes the preparation of tissue specific knock-outs of the *EPM2B* gene.

The following non-limiting example is illustrative of the present invention:

5 **EXAMPLES**

Example 1

The inventors examined all available databases and found 7 annotated genes in the newly defined critical region on chromosome 6p22.3 (Figure 1). Based on their predicted functional characteristics each gene was prioritized
10 for mutation screening through DNA sequencing of LD patients carrying an *EPM2B* haplotype, but no pathogenic variants were identified. Simultaneously, the inventors' analysis led to the discovery of a previously uncharacterized apparently single-exon (1188 bp) gene sharing extensive sequence identity with orthologous units (with equivalent protein-coding
15 potential) in other higher vertebrates (75%, 78%, 87% nucleotide identity with rat, mouse, and dog, respectively). The human gene, designated as *EPM2B*, also had at its 5'-end all of the proposed features of the consensus sequence of an eukaryotic translational initiation site and, at its 3'-end, two putative polyadenylation signals (Figure 1). Moreover, expressed sequence tag (EST)
20 and cDNA data in human and mouse supported that the single-exon unit was a *bona fide* gene.

EPM2B would be predicted to encode a 395 amino acid (aa) protein that the inventors have named malin (*mal* for seizure in French) containing a zinc finger of the RING type in the N-terminal half and 6 NHL-repeat domains
25 in the C-terminal direction (Figure 1). Specifically, the zinc-binding RING-finger motif (C-X₂-C-X₁₆-C-X₁-H-X₂-C-X₂-C-X₁₄-C-X₂-C) was identified (E-value of 0.0067) between residues 26-71 of malin consistent with the signature sequence (C-X₂-C-X₉₋₃₉-C-X₁₋₃-H-X₂₋₃-H-X₂-C-X₄₋₄₈-C-X₂-C) of the RING-HC type (16,17). The presence of a RING finger is predictive of an E3
30 ubiquitin ligase function (8,9,18). E3 ligation is the final and specific step of the ubiquitin pathway transferring ubiquitin from E2, either directly or through adaptor proteins, to a specific substrate(s) to initiate its removal by the

proteasome system⁸. The 6 NHL domains (10-13) were predicted on the basis of presence of an approximately 44-residue motif rich in glycine and hydrophobic amino acids seeded with a cluster of charged residues (Pfam detected six trusted matches for NHL domains with E-values ranging from 5 0.011 to 3.5) (Figure 1).

Northern-blot analysis indicated *EPM2B* is present (as at least two transcripts 1.5kb and 2.4kb in size) in all tissues examined including specific sub-regions of the brain (Figure 3). The observed transcript sizes correspond near to the lengths expected between the predicted ATG-start site and the 10 two different polyadenylation signals (Figure 1). Moreover, the expression profile was similar to that observed for *EPM2A*, both being present in all tissues in which Lafora bodies have been observed (2,19).

The complete coding region of *EPM2B* was sequenced in a cohort of 34 LD probands previously shown not to carry mutations in *EPM2A*. To date, 15 17 different DNA sequence alterations have been found in *EPM2B* in 26 families including 8 deletions and 1 insertion leading to frame-shifts, 7 missense, and 1 non-sense change (Table 1). These mutations were found in families in both homozygous (18) and compound heterozygous (8) recessive states. The four consanguineous F-C families used in the original linkage 20 study all carried a homozygous 76T>A change producing a cysteine-to-serine alteration in one of the 7 conserved cysteine residues that are critical for the zinc-binding ability of the RING-finger domain (Figure 2b). The most common mutation identified (7 families) was a homozygous 205C>G transition resulting in a proline to alanine change in the RING-finger domain. The LD38324 family 25 that was critical in refining the *EPM2B* locus (Figure 2a) carried a homozygous 2-bp deletion (1048-1049delGA) leading to a frame-shift mutation in the fifth NHL-domain (Figure 2b). In total, 88% of the LD families can now be accounted for by mutations in *EPM2A* (48%) and *EPM2B* (40%). The observation of 8 families with no detectable mutations in either of these 30 genes suggests there could be additional LD loci.

Among other conditions with polyglucosan accumulation, including adult polyglucosan body disease (APBD) (20), LD is unique for the sub-

cellular location of inclusions in neuronal dendrites but not axons (21), as is show in Figure 4. The physical association of the forming polyglucosan fibrils with ER is also specific to LD (3). In APBD, which is caused by mutations in the glycogen branching enzyme (20,22,23), polyglucosans are indistinguishable in size, composition, and number from Lafora bodies, but they are located exclusively in the cell soma and axons (20). The presence of a seizure phenotype in LD but not in APBD implicates ER-associated dendritic accumulations of polyglucosans in the epilepsy of LD.

To examine the cellular localization of malin the inventors transfected an epitope-tagged *EPM2B* construct and found that it did indeed localize at the ER and to a lesser extent within the nucleus of cultured cells (Figure 5). These results were similar to the cellular localization observed for the two alternative transcripts (A and B) of *EPM2A*, which encode isoforms of laforin found in the cytoplasm at the ER (24-26) (Figure 4b) and in the nucleus, respectively (27). The inventors most recent data implicate loss of function of the cytoplasmic form of laforin in LD based on the identification of transcript A-specific mutations (L.I. et al., manuscript submitted). Moreover, the study of murine-*Epm2a* knockouts (28) and LD patients (1,2) has shown that the ER-associated polyglucosan bodies precede or are concomitant, respectively, with onset of epilepsy.

Therefore, in the simplest explanation, LD arises due to improper clearance, and subsequent accumulation of polyglucosans in dendrites, disturbing neuronal synaptic function leading to epileptogenesis. The inventors have now shown in transgenic LD mice that laforin contacts polyglucosans (and not glycogen) providing the first physical link between a disease gene product and LD pathology (E.M.C. et al., in preparation). Laforin's only other experimentally-validated function is that of a dual-specificity phosphatase (24,25), which would predict that there is at least one phosphoprotein intermediary through which it acts. Possible candidates could be the newly discovered *EPM2AIP1* laforin-interacting protein (26), or other still to be cloned LD gene(s), or any of their interacting proteins. Malin will likely be involved via specific protein-protein interaction through its NHL

domains followed by ubiquitin-mediated removal of a regulatory target(s), contributing a crucial role with laforin to safeguard neurons against Lafora bodies and epilepsy.

METHODS

5 Samples

All patients described in this study were formally diagnosed with adolescent-onset progressive myoclonus epilepsy based on presence of pathognomonic Lafora bodies in biopsies of skin, skeletal muscle, liver or brain. Each LD individual and their family members (if available) were
10 examined for involvement of the *EPM2A* locus at 6q24 by homozygosity mapping, mutation screening, or both.

Genotyping and Mutation Screening

Information and amplification conditions on the established (*D6S274*, *D6S285*, *D6S966*, *D6S1567*, *D7S1678*, *D6S1688*, *D6S1959*) and new
15 (*BV012563*, *BV012730*, *BV012565*, *BV012566*, *BV012568*) are found in the UniSTS and Entrez Nucleotides database (<http://www.ncbi.nlm.nih.gov/>). DNA Sequence variations were detected by sequencing of PCR-products. To screen *EPM2B*, two sets of primer pairs that amplify overlapping fragments were used *EPM2B*-1F: (5'-ACTGTGACCGTG ACCGAGA-3') and *EPM2B*-1R:
20 (CACACCCCAAGGTAAGGAGA-3'); *EPM2B*-2F: (5'-GACTGCCATGTGGTTGTCAC-3') and *EPM2B*-2R: (5'-AAACAATTCATTAATGGCAGCA-3') (see Figure 1). PCR was performed on 50 ng of DNA in buffer [75 mM Tris-HCl (pH 8.8), 20 mM (NH₄)₂SO₄, 0.01% Tween 20, 1.5 mM MgCl₂, 1M Betaine, 0.2 mM dNTP, 0.2 uM of each primer,
25 2.5 Units of Taq Polymerase (MBI Fermentas)]. Cycling conditions were: initial denaturation at 94°C for 3 min followed by 35 cycles of denaturation at 94°C for 30 sec, annealing at 60°C for 30 sec and extension at 72°C for 30 sec, with a 10 min final extension at 72°C. PCR products were purified using microCLEAN (Microzone Ltd). 3µl (100ng/µl) of purified PCR product was
30 used as sequencing template. For all reactions, 1µl (5 pmol) of primer, 1.5µl 5X sequencing buffer (Applied Biosystems), 1µl BigDye Terminator v3.1, and 7.5µl H₂O in a 14µl reaction volume were used. Thermocycling (MJ

Research, Inc.) conditions were denaturing at 96°C for 30s; annealing at 50°
for 20s; and extension at 60°C for 4 min; 35 cycles. All reactions were
subsequently purified using multiscreen-HV filter plates (Millipore) and
analyzed using an ABI-3700. All sequence variants detected in LD patients
5 were examined in a collection of 50 (100 chromosomes) randomly selected
DNA samples.

Gene identification and Northern blots

Gene annotation data and EST sequences were mainly obtained from
the University of California Santa Cruz (UCSC) genome browser
10 (<http://genome.ucsc.edu/>) and Celera Genomics (<http://www.celera.com/>).
Additional putative genes were annotated using the Genescript algorithm
(<http://tcag.bioinfo.sickkids.on.ca/genescript/>) and multi-species VISTA
(<http://www-gsd.lbl.gov/vista/>) alignments between human and mouse
sequence. The RING finger domain was predicted by Pfam, Prosite,
15 InterProScan, SMART and MotifScan. NHL domains were identified using
Pfam and InterProScan. *EPM2B* orthologues were identified using BLASTN
and BLASTP analyses against the GenBank non-redundant database.
Prediction of the sub-cellular localization of malin by sequence analysis was
performed using PSORT II. No significant signal peptide sequence (for
20 recognition of ER, Golgi complex, lysosome and integral plasma membrane
proteins), mitochondrial targeting sequence, nuclear localization signal and
peroxisomal targeting signal was identified. The human multiple-tissue blot I
and human brain blot II (Clontech) were probed with a [³²P]dCTP-labeled
probe that was generated using the primers 5'-
25 GTCACCATCACCAACGACTG-3' and 5'-TGCGAAAGACCATGAGTGAC-3',
which amplified a 557bp fragment within the coding region of *EPM2B*.
Hybridization and washing conditions were performed according to the
manufacturer's instructions.

Sub-cellular localization and Electron Microscopy

30 The myc-tagged *EPM2A* transcript A expression construct
(pcDNA3myc*EPM2A*), which encodes the cytoplasmic isoform of laforin has
been described (24). A myc-tagged *EPM2B* construct was generated

(pcDNA3mycEPM2B) using the same general protocols. Full-length *EPM2B* was amplified by PCR from genomic DNA using the (forward) primer (5'-ggatccATGgcggccgaagc-3') containing a *Bam*HI restriction site (underlined) and the start codon (uppercase) and a (reverse) primer (5'-gcggccgccacaattcattaatggcagac-3') containing a *Not*I site (underlined). This product was cloned into the corresponding sites of the mammalian expression vector pcDNA3 (Invitrogen). Myc was then introduced, in frame, after amplifying from a previous myc-containing vector with 5' *Kpn*I-tagged and 3' *Bam*HI-tagged primers. pcDNA3mycEPM2A and pcDNA3mycEPM2B (2 mg) were transfected into Cos-7 cells using Lipofectamine-Plus (Invitrogen) and exposed to lipid-DNA complex in DMEM (Sigma-Aldrich) for 5 hours. Forty-eight hours post-transfection, cultures were rinsed twice in PBS and fixed for 15 min at -20°C in an acetone:methanol (1:1) mix. They were then stained with antibodies against myc-laforin and ER marker GRP94. Cultures were blocked for 1 hour (10% BSA/PBS) and incubated with anti-Myc and anti-ER for 45 min at room temperature. Slides were washed with PBS and incubated with secondary antibody (FITC-labeled goat anti-mouse, 1:400, detectable through the green filter; Texas red-labeled donkey anti-goat, 1:400, detectable through the red filter; Jackson ImmunoResearch Laboratories) in blocking solution. Following mounting (Dako Anti-Fade), they were analyzed by immunofluorescence light microscopy. For electron microscopic examination biopsy material was obtained from the LD patient and placed into chilled Universal fixative. Using standard protocols it was then analyzed at the ultra-structural level.

While the present invention has been described with reference to what are presently considered to be the preferred examples, it is to be understood that the invention is not limited to the disclosed examples. To the contrary, the invention is intended to cover various modifications and equivalent arrangements included within the spirit and scope of the appended claims.

All publications, patents and patent applications are herein incorporated by reference in their entirety to the same extent as if each

-43 -

individual publication, patent or patent application was specifically and individually indicated to be incorporated by reference in its entirety.

FULL CITATIONS FOR REFERENCES REFERRED TO IN THE SPECIFICATION

- 5 1. Lafora, G.R., Gluck, B. Beitrag zur histopathologie der myoklonischen epilepsie. Z Ges Neurol Psychiat 6, 1-14 (1911).
2. Minassian, B.A. Progressive myoclonus epilepsy with polyglucosan bodies: Lafora disease. Adv Neurol 89, 199-210 (2002).
3. Collins, G.H., Cowden, R.R. & Nevis, A.H. Myoclonus epilepsy with Lafora
10 bodies. An ultrastructural and cytochemical study. Arch Pathol 86, 239-54 (1968).
4. Sakai, M., Austin, J., Witmer, F. & Trueb, L. Studies in myoclonus epilepsy (Lafora body form). II. Polyglucosans in the systemic deposits of myoclonus epilepsy and in corpora amylacea. Neurology 20, 160-76
15 (1970).
5. Minassian, B.A. et al. Genetic locus heterogeneity in Lafora's progressive myoclonus epilepsy. Ann Neurol 45, 262-5 (1999).
6. Minassian, B.A. et al. Mutations in a gene encoding a novel protein tyrosine phosphatase cause progressive myoclonus epilepsy. Nat Genet
20 20, 171-4 (1998).
7. Minassian, B.A. et al. Mutation spectrum and predicted function of laforin in Lafora's progressive myoclonus epilepsy. Neurology 55, 341-6 (2000).
8. Jackson, P.K. et al. The lore of the RINGs: substrate recognition and catalysis by ubiquitin ligases. Trends Cell Biol 10, 429-39 (2000).
- 25 9. Hatakeyama, S. & Nakayama, K.I. U-box proteins as a new family of ubiquitin ligases. Biochem Biophys Res Commun 302, 635-45 (2003).
10. Fridell, R.A., Harding, L.S., Bogerd, H.P. & Cullen, B.R. Identification of a novel human zinc finger protein that specifically interacts with the activation domain of lentiviral Tat proteins. Virology 209, 347-57 (1995).
- 30 11. Frank, D.J. & Roth, M.B. ncl-1 is required for the regulation of cell size and ribosomal RNA synthesis in *Caenorhabditis elegans*. J Cell Biol 140, 1321-9 (1998).

12. Slack, F.J. & Ruvkun, G. A novel repeat domain that is often associated with RING finger and B-box motifs. *Trends Biochem Sci* 23, 474-5 (1998).
13. Slack, F.J. et al. The lin-41 RBCC gene acts in the C. elegans heterochronic pathway between the let-7 regulatory RNA and the LIN-29 transcription factor. *Mol Cell* 5, 659-69 (2000).
14. Serratosa, J.M. et al. A novel protein tyrosine phosphatase gene is mutated in progressive myoclonus epilepsy of the Lafora type (EPM2A). *Hum Mol Genet* 8, 345-52 (1999).
15. Chan, E.M. et al. Genetic mapping of a new Lafora Progressive Myoclonus Epilepsy locus (EPM2B) on 6p22. *Journal of Medical Genetics* (in press).
16. Freemont, P.S. The RING finger. A novel protein sequence motif related to the zinc finger. *Ann N Y Acad Sci* 684, 174-92 (1993).
17. Saurin, A.J., Borden, K.L., Boddy, M.N. & Freemont, P.S. Does this have a familiar RING? *Trends Biochem Sci* 21, 208-14 (1996).
18. Freemont, P.S. RING for destruction? *Curr Biol* 10, R84-7 (2000).
19. Schwarz, G.A. & Yanoff, M. Lafora disease, distinct clinico-pathological form of Unverricht's syndrome. *Arch Neurol* 12, 172-188 (1965).
20. Robitaille, Y., Carpenter, S., Karpati, G. & DiMauro, S.D. A distinct form of adult polyglucosan body disease with massive involvement of central and peripheral neuronal processes and astrocytes: a report of four cases and a review of the occurrence of polyglucosan bodies in other conditions such as Lafora's disease and normal ageing. *Brain* 103, 315-36 (1980).
21. Cavanagh, J.B. Corpora-amylacea and the family of polyglucosan diseases. *Brain Res Brain Res Rev* 29, 265-95 (1999).
22. Thon, V.J., Khalil, M. & Cannon, J.F. Isolation of human glycogen branching enzyme cDNAs by screening complementation in yeast. *J Biol Chem* 268, 7509-13 (1993).
23. Lossos, A. et al. Adult polyglucosan body disease in Ashkenazi Jewish patients carrying the Tyr329Ser mutation in the glycogen-branching enzyme gene. *Ann Neurol* 44, 867-72 (1998).

24. Minassian, B.A. et al. Laforin is a cell membrane and endoplasmic reticulum-associated protein tyrosine phosphatase. *Ann Neurol* 49, 271-5 (2001).
25. Ganesh, S. et al. Laforin, defective in the progressive myoclonus epilepsy of Lafora type, is a dual-specificity phosphatase associated with polyribosomes. *Hum Mol Genet* 9, 2251-61 (2000).
26. Ianzano, L., Zhao, X.C., Minassian, B.A., Scherer, S.W. Identification of a novel protein interacting with laforin, the EPM2A Progressive Myoclonus Epilepsy gene product. *Genomics* 81, 579-587 (2003).
27. Ganesh, S., Suzuki, T. & Yamakawa, K. Alternative splicing modulates subcellular localization of laforin. *Biochem Biophys Res Commun* 291, 1134-7 (2002).
28. Ganesh, S. et al. Targeted disruption of the Epm2a gene causes formation of Lafora inclusion bodies, neurodegeneration, ataxia, myoclonus epilepsy and impaired behavioral response in mice. *Hum Mol Genet* 11, 1251-62 (2002).
29. Kozak, M. Interpreting cDNA sequences: some insights from studies on translation. *Mamm Genome* 7, 563-74 (1996).
30. Lovering, R. et al. Identification and preliminary characterization of a protein motif related to the zinc finger. *Proc Natl Acad Sci U S A* 90, 2112-6 (1993).

Table 1. *EPM2B* mutations identified in LD patients.

Family	Origin	Nucleotide change	Predicted Effect
LD6	F-Canada	Homozygous 76T>A	C26S (missense RING finger)
LD7	F-Canada	Homozygous 76T>A	C26S (missense RING finger)
LD27	F-Canada	Homozygous 76T>A	C26S (missense RING finger)
LD28	F-Canada	Homozygous 76T>A	C26S (missense RING finger)
LD23102	Brazil	Homozygous 205C>G	P69A (missense RING finger)
LDlaf100	Brazil	Homozygous 205C>G	P69A (missense RING finger)
LD5922	Italy	Homozygous 205C>G	P69A (missense RING finger)
LDlaf26	Italy	Heterozygous 205C>G 838G>A	P69A (missense RING finger) E279K (missense NHL 4)
LD41818	Spain	Heterozygous 205C>G 468delA	P69A (missense RING finger) G158fs173 (frameshift)
LD35180	F-Canada	Heterozygous 205C>G 204delC	P69A (missense RING finger) P69fs21 (frameshift RING finger)
LD29852	United States	Heterozygous 205C>G 468-469delAG	P69A (missense RING finger) G158fs16 (frameshift)
LD34477	India	Heterozygous 468-469delAG 676C>T	G158fs16 (frameshift) Q226X (nonsense NHL 3)
LD51	Brazil	Homozygous 468-469delAG	G158fs16 (frameshift)
LDlaf101	Italy	Homozygous 468-469delAG	G158fs16 (frameshift)
LDlaf9	Yugoslavia	Heterozygous 992delG 468-469delAG	G321fs2 (frameshift NHL 5) G158fs16 (frameshift)
LDlaf1	Yugoslavia	Heterozygous 992delG 468-469delAG	G321fs2 (frameshift NHL 5) G158fs16 (frameshift)
LD949	Bosnia	Homozygous 992delG	G321fs2 (frameshift NHL 5)
LD38324	Yugoslavia	Homozygous 1048-1049delGA	E340fs40 (frameshift NHL 5)
LD7635	Israel	Homozygous 373-382del10bp	T125fs103 (frameshift)
LD628	Italy	Homozygous 661-692del32bp	V16fs1 (frameshift NHL 3)
LD483	Italy	Homozygous 260T>C	L87P (missense)
LD22830	Canada	Homozygous 905A>C	Q29P (missense NHL 4)
LD32817	Pakistan	Homozygous 98T>C	F33S (missense RING finger)
LD25-9	Saudi Arabia	Homozygous 892ins2T	S298fs15 (frameshift NHL 4)
LD5487	Denmark	Heterozygous 436G>A 1100delT	D146N (missense NHL 1) V362fs20 (frameshift)
LD5489	Denmark	Homozygous 1100delT	V362fs20 (frameshift)

- 5 *EPM2B* mutations have been identified in 26 families. In family LD51, DNA from the proband was not available but the parents were both heterozygous carriers of 468-469delAG, which would be predicted to lead to homozygous frame-shift mutations in the LD child. All of the mutations detected would affect the putative RING or NHL motifs, or would be predicted to lead to a frame-shift or cause drastic structural change in the protein (LD483 carries a 260T>C nucleotide change which would lead to a leucine to proline alteration). Four silent DNA sequence-coding variants were identified. Three of them T312C (H104H), G372C (G124G) and T1020C (G340G) were present in five, two, and one of 100 control chromosomes, respectively. The most common polymorphism detected, C332T (P111L) (Figure 1) was observed on 42 of 100 control chromosomes.
- 10

WE CLAIM:

1. An isolated nucleic acid molecule encoding a protein with a RING-finger domain and 6 NHL-motifs wherein the protein is associated with Lafora's disease.
2. A nucleic acid according to claim 1 having a sequence as shown in SEQ ID NO:1 (Figure 6A) or SEQ ID NO:3 (Figure 7).
3. An isolated nucleic acid molecule according to claim 1 comprising
 - (a) a nucleic acid sequence as shown in SEQ ID NO:1 (Figure 6A) and SEQ ID NO:3 (Figure 7A), wherein T can also be U;
 - (b) a nucleic acid sequence complementary to (a);
 - (c) a nucleic acid sequence that has substantial sequence homology to a nucleic acid sequence of (a) or (b);
 - (d) a nucleic acid sequence that is an analog of a nucleic acid sequence of (a), (b) or (c); or
 - (e) a nucleic acid sequence that hybridizes to a nucleic acid sequence of (a), (b), (c) or (d) under stringent hybridization conditions.
4. A method of detecting Lafora's disease comprising detecting a mutation or deletion in a nucleic acid sequence according to any one of claims 1 to 3 in a sample from an animal.
5. A method according to claim 4 comprising detecting a C to G change in nucleotide number 205 of the sequence shown in SEQ ID NO:1 (Figure 6).
6. A method according to claim 4 comprising detecting a T → A mutation at position 76 in the *EPM2B* gene (SEQ ID NO:1).
7. A method according to claim 4 comprising detecting a deletion of GA at positions 1048 and 1049 in the *EPM2B* gene (SEQ ID NO:1).

8. A method according to claim 4 comprising detecting a mutation in the *EPM2B* gene as indicated in Table 1.
- 5 9. An isolated protein containing a RING-finger domain and six NHL domains which protein is associated with Lafora's disease.
10. A protein according to claim 9 having the amino acid sequence as shown in SEQ.ID.NO.:2 (Figure 6B) or SEQ ID NO:4 (Figure 7).
- 10 11. A method for detecting Lafora's disease comprising detecting a mutation in a protein according to any one of claims 9 or 10.
12. A method according to claim 11 comprising detecting a mutation in the
- 15 *EPM2B* gene as indicated in Table 1.

ABSTRACT OF THE DISCLOSURE

A novel gene (*EPM2B*) that is mutated in people with Lafora's disease
5 is described.

Fig 1




Fig 2a




Fig 2b




Fig 3




Fig 4




Fig 5a




Fig 5b




Fig 6A

EPM2B gene sequence

EPM2B ORF is in uppercase
Transcript : 2134bp

gcacaggacgcgcc
ATGGCGGCCGAAGCCTCGGAGAGCGGGCCAGCGCTGCATGAGCTCATGCG
CGAGGCGGAGATCAGCCTGCTCGAGTGCAAGGTGTGCTTTGAGAAGTTTG
GCCACCGGCAGCAGCGCGCCCGCGCAACCTGTCTGCGGCCACGTGGTC
TGCCTGGCCTGCGTGGCCGCCCTGGCGCACCCGCGCACTCTGGCCCTCGA
GTGCCCATTCTGCAGGCGAGCTTGCCGGGGCTGCGACACCAGCGACTGCC
TGCCGGTGTGTCACCTCATAGAGCTCCTGGGCTCAGCGCTTCGCCAGTCC
CCGGCCGCCCATCGCGCCGCCCCAGCGCCCCCGAGCCCTCACCTGCCA
CCACACCTTCGGCGGCTGGGGGACCCTGGTCAACCCACCGGACTGGCGC
TTTGTCCCAAGACGGGGCGTGTCTGTGGTGGTGCACGACGGCAGGAGGCGT
GTCAAGATTTTTGACTCAGGGGGAGGATGCGCGCATCAGTTTGGAGAGAA
GGGGGACGCTGCCAAGACATTAGGTACCCTGTGGATGTACCATCACCA
ACGACTGCCATGTGGTTGTCACTGACGCCGGCGATCGCTCCATCAAAGTG
TTTGATTTTTTTGGCCAGATCAAGCTTGTCAATTGGAGGCCAATTCTCCTT
ACCTTGGGGTGTGGAGACCACCCCTCAGAATGGGATTGTGGTAACTGATG
CGGAGGCAGGGTCCCTGCACCTCCTGGACGTCGACTTCGCGGAAGGGGT
CTTCGGAGAAGTCAAAGGTTGCAAGCTCATCTGTGCAATCCCCGAGGGGT
GGCAGTGTCTTGGCTCACCGGGCCATTGCGGTCTTGGAGCACCCCTGG
CCCTGGGGACTGGGGTTTGACAGCACAGGGTGAAAGTGTTTAGCTCAAGT
ATGCAGCTTGTGCGCCAAGTGGATAACCTTTGGGCTGAGCCTCTACTTTCC
CTCCAAAATAACTGCCCTCCGCTGTGACCTTTGATCACCAGGGAAATGTGA
TTGTTGCAGATACATCTGGTCCAGCTATCCTTTGCTTAGGAAAACCTGAG
GAGTTTCCAGTACCGAAGCCCATGGTCACTCATGGTCTTTTCGCATCCTGT
GGCTTCTACCTTACCAAGGAGAATTCTCTTCTTGTGCTGGACACAGCAT
CTCATTTCTATAAAAGTCTATAAAAGTTGACTGGGGGTGAtgggctggggtg
ggctccctggaatcagaagcactagtgtgccattaatgaattgtttaacc
ctggataagtcacttaaaactcatctatccaggcagggataattaaaacca
tctggcagacttacaaagcttgggacagttattggagattaatctaccat
ttattgaatgcataactctgtgcaaggaaatttgcaaatattagcttattt
aatctgtactatccagtgaggttaatttcttccccccaagatagagtcaa
gctctgtcaccaggtggagtgcagaagcatgatcacagctcactacag
tttcaacgtcccccgctcaggtggtccttcacctcagcctcccaagtag
ctgggaccacaagtgtgcattaccacactcagctaatttttgatatttg
cagagatggggtttcaccatggtgcccaggctgggtctcaaactcctgagt
tcaagcaatccaccttcctcggcctcccaaagtaactaggagtacaggcat
agccacttgctcagccataatttttattattaatctcattgtacaagtga
gaaaactgagaccagagagcttaagtgacttcctcgaggtcatagttac
ttactgccttagtcccaatttgaattcaattctgattccaaataagttgc
gcttaataaagacaacagatgtgggaaaaatatgtgaatgtgtagtgtg
ctatgtgtactgtctttacaagtagctaattatttttagcacaagatgtg
caaagaaaggagactttatggagagttcaggagaaaaaggattttgtggg
ggccatcactttcattcaatttgcgactgctctgatggcacattagatga
agttactgttgatcctgagttacgtgaataagaaaaacaattgaactgct
tattaaaaaagtaaacatgt

Fig 6B

EPM2B protein sequence

MAAEASESGPALHELMREAEISLLECKVCFEKFGRQRRPRNLSCGHVV
CLACVAALAHPRTLALECPFCRRACRGCDTSDCLPVLHLIELLGSALRQS
PAAHRAAPSAPGALTCHHTFGGWGTLVNPTGLALCPKTGRVVVVHDGRRR
VKIFDSGGGCAHQFGEKGDAADIRYPVDVTITNDCHVVVTDAGDRSIKV
FDFFGQIKLVIGGQFSLPWGVETTPQNGIVVTD AEAGSLHLLDVDF AEGV
LRRTERLQAHL CNPRGVAVSWLTGAI AVLEHPLALGTGVCSTRVKVFSSS
MQLVGQVDTFGLSLYFPSKITASAVTFDHQGNVIVADTSGPAILCLGKPE
EFPVPKPMVTHGLSHPVALTFTKEN SLLVLDTASHSIKVYKVDWG

Fig 7A

Promoter (5') sequence:

```

1  CCCCAGGGCC CCCCCGGGCC CCAGGCAACC CCAGGCCCCC AGGCAACCCA
51  AGGCCCCCCC GCCCCAAGCC CCCCAGGTTC CCGCCCCCAA GAACCAAGCC
101 CCCCAGGGCC CCGCCCCCAG CACCCAGCAC CAAGCCCCCG CCCCCCGGCC
151 CAAGCAACCA GCCCCAGCAC CCAGCCCCCG CCCCAGCCCC AGCCCCAGCA
201 CCGAGCCCCC GCCCCAGCAC CCAGCCCCAG CACCCAGCCC CCGCCCCAGC
251 CCGAGCCCCC GTCCCCCCCC CCAGCAACCA GCCCCAGCCC CAGCAGCAGC
301 ACCCAGCAGG GCACTGCAAA GCGTAGGCTA CCCCAGGTGG AACACCGTGT
351 TCTAGTTTTC CTTTGCCGTT TGCAGCCTGG GCGATCGGGG GCCACCGCTC
401 GAGCCTGTTT CCGTTCGGGG AAAGCGGAGC CCGCCCCGCC CCGCCCCCGC
451 CTGCCGGAAG GTCAAGGGCC TGGGCTGGGG GCGCGCGGTG CCGCCCCGGA
501 GCGTCGCTC CCGCGCCCTC CGCAGTCAGC GCGCGCCGCG CCGCGCGGGG
551 ACGCAGGCCC GCGCGGAGA GCGTCGCGGC TCGCGCCGCG ACGTCAGGCC
601 CCGCCCCGCC CCGCCCCGCC CCGTGACCGG CCGCGCCCCC GCGCCCCGCC
651 CCGCCCCCGG ACGCAGGCGC GCGCGCGGGA GCGCGCGCGG CCGCGCGG

```

Coding sequence:

```

      ATG
701  GGGGCCGAG CCGCGGGGAG CCGCGGGGCG CTGCGGGAGC TGGTGCGCGA
751  GCGCGAGGTC AGCTTGCTCG AGTGCAAGGT GTGCTTGGAG AGGTTGGGCC
801  ACCGCCAGCA GCGCGCCCCG CGCAACCTGC CTTGCGGCCA CGTGGTGTGC
851  CTGGCCTGGG TGGCGGCCCT GCGGCAACCG CCGAGCGCTG CCTGGAGTGC
901  CCGCTTCTGC CGCGCGGCTT GCGCGGCTTG CGACACCAGC GACTGCGCTC
951  CCGTGCCTCA CCTCTGGAG CTTCTGGGCT CCGCGCTGGG CCGAGCCCCC
1001 GCGCGCCCCC GCGCGCCCCC CCGCGCCCCC CCTGCGGCC CCGCGGCCCT
1051 CGCTGGCCAT CACGGTTTGG GAGGCTGGGG GACCTGGTTC AACCCACGG
1101 GGCTGGGCT GTGCCCCAAG ACCGCGCGGG TGTGGTGGT GCAAGAGGCG
1151 AGGAGGCGGG TCAAGATCTT TCACTCCGGG GGAGGATGGG CCGATCAGTT
1201 TGGAGAGAAG GGGGAGGCTG CCGAGGACAT TAGGTACCCC CTGGAAGTGG
1251 CCGTCAACCA CCACTGCCAC GTGGTTGTCA CCGACGCGCG CCAAGCTTCC
1301 ATCAAAGTGT TTGATTTCTT TGGCCAGATC AAGCTGTTCA TTGGAGACCA
1351 GTTTTCTTCA CCTTGGGGGG TGGAGACCAC CCTCAGAAAT GGGGTGGTGG
1401 TAACTGACGC CGAGGCAAGG TCGCTGCACC TGCTGGAAGT CCACTTTGCA
1451 GAAGGAGCCC TCAGAGGAGC TGAAAAGCTG CAAGGTCAATC TGTGCAACCC
1501 GCGAGGGGTG GCGGTGTCTT GGTCTACTGG GCGCATTTGG GTCTGGAGC
1551 ACGCTCCGGG GCTGGGGGCT GGGGCGGGCA GCAACGCGGT GAAGGTGTTT
1601 AGOCCAACTA TGCAGCTGAT CCGGAGGTTG GATACTTTTG GGCTCAGCCT
1651 CTTTTTCCCC TCTAGATAAA CCGCTCCGCG CGTGACCTTT GATCACCAGG
1701 GGAATGTGAT TGTTCAGAT ACTTCTAGTC AGGCGTCTCT ATGCTTGGGA
1751 GCACCTGAGG AATTTCAGT CCGAAGGCC ATCATCACCC ATGGTCTTTT
1801 CCATCTGTG GCACTGACCT TCACCAAGGA GAATCTCTTT CTGTGCTGG
1851 ACAGTGACAG CCAATTCGTA AAAGTCTACA AGGCTGACTG GGGGTAA

```

Fig 7A (cont'd)

3' UTR:

TGG

1901	GGTGTGGTGG	GGGTCTGGA	ACTGOCCTA	ATCCAGTTTA	ACCCTGGATG
1951	AATTAAATCCC	ATCTCTCGAA	CGGGGATCAT	TATAACTGCC	TGACGAGCTT
2001	ATAAAGGTTG	AAGGTAATTA	TTAAAGAATA	ATAATGAAGT	CTACCGTTTA
2051	TTGAGTTATG	TGCTCCCTGT	GCTAGGAAAC	TTTGCAAATA	TTAGCTCAGC
2101	GTGTCTTAC	AGTGGTACCC	AGGGAGGTAA	TGCCCCATCAT	TAATCCCAT
2151	TTAGAGATGA	GAAAACTGAG	AACCGAGGGT	TAAAGTGATT	CTCTGAAGGT
2201	CATGTTTACT	TACTGTGACA	GTCACAATGG	GAACTCTATT	CTGACTCCCC
2251	AATCCCTTGC	TCCTAAGTAG	GATAACAGAT	GTCAGAAAAC	GACAGCATGT
2301	GTCTATATGT	TGTACTGTG	TGTACTCTCT	TTACAGGTAG	CTATTTCTCT
2351	TGGTTGGAAG	TGCAGAGAAA	GGAGACTTTC	TAGAGAGTTC	AAGAGGAAAA
2401	AGGGTAGTGT	GATGAGCATG	GAAGTGAGTG	TCATTGAACT	TGCTGGTTCT
2451	TTGATGTCAC	AGTAGGTAGA	ATGACTGTGG	ATCCTTCAAC	TGCCCTTGGG
2501	AAAGGTAAAC	ATGTCGTGTG	GGACCTGGAT	GTCCTCCATC	ATAGCAACCC
2551	AGGAAATACT	AGTTGGTTGC	TGCAGAAAGG	CTGTGTGGA	CATAAGTTCA
2601	AAACTACTGC	CGAACACCGT	ACATTACAC	ACCTCCAGTG	GGAGATGGCT
2651	GGAAGACAGT	CCTGTGACAG	GTCTGCATT	ATAGAACAAAG	ANGCCGCCAC
2701	CGTTGGTTCA	CGGCAGAAAG	AGTTTGCCCTG	CCTCTTCATA	ATCTGTGNON
2751	ACCCGAAACC	CTTTTGIGAT	AGAGTTTTC	TCGTGCCAT	TTNAATTGT
2801	CCCATGTGAC	ACACTGTTT	CCCTTAAOCA	GCTCCCTTGA	TGCTNAGCTA
2851	GCAATTAGGC	CACCTGGTAAA	CCCTGTATA	CTCTTGAGT	TGAAGTTAAG
2901	CTTTGACCCA	GATAANGNCT	GCTTTAATAC	NIGCAGTGA	NTGGACOGAA
2951	TAAGGGGGAA	ATTTCAAGTG	AGGTGGCCGG	GTTCTTTATN	AACCGGTTTT
3001	GGTTTGTA				

Fig 7B

Met	Gly	Ala	Glu	Ala	Ala	Gly	Ser	Gly	Arg	Ala	Leu	Arg	Glu	Leu	Val	1	5	10	15
Arg	Glu	Ala	Glu	Val	Ser	Leu	Leu	Glu	Cys	Lys	Val	Cys	Phe	Glu	Arg	20	25	30	
Phe	Gly	His	Arg	Gln	Gln	Arg	Arg	Pro	Arg	Asn	Leu	Pro	Cys	Gly	His	35	40	45	
Val	Val	Cys	Leu	Ala	Cys	Val	Ala	Ala	Leu	Ala	His	Pro	Arg	Thr	Leu	50	55	60	
Ala	Leu	Glu	Cys	Pro	Phe	Cys	Arg	Arg	Ala	Cys	Arg	Gly	Cys	Asp	Thr	65	70	75	80
Ser	Asp	Cys	Leu	Pro	Val	Leu	His	Leu	Leu	Glu	Leu	Leu	Gly	Ser	Ala	85	90	95	
Leu	Arg	Pro	Ala	Pro	Ala	Ala	Pro	Arg	Ala	Ala	Pro	Arg	Ala	Ala	Pro	100	105	110	
Cys	Ala	Pro	Gly	Ala	Leu	Ala	Cys	His	His	Ala	Phe	Gly	Gly	Trp	Gly	115	120	125	
Thr	Leu	Val	Asn	Pro	Thr	Gly	Leu	Ala	Leu	Cys	Pro	Lys	Thr	Gly	Arg	130	135	140	
Val	Val	Val	Val	His	Asp	Gly	Arg	Arg	Arg	Val	Lys	Ile	Phe	Asp	Ser	145	150	155	160
Gly	Gly	Gly	Cys	Ala	His	Gln	Phe	Gly	Glu	Lys	Gly	Glu	Ala	Ala	Gln	165	170	175	
Asp	Ile	Arg	Tyr	Pro	Leu	Asp	Val	Ala	Val	Thr	Asn	Asp	Cys	His	Val	180	185	190	
Val	Val	Thr	Asp	Ala	Gly	Asp	Arg	Ser	Ile	Lys	Val	Phe	Asp	Phe	Phe	195	200	205	
Gly	Gln	Ile	Lys	Leu	Val	Ile	Gly	Asp	Gln	Phe	Ser	Leu	Pro	Trp	Gly	210	215	220	

Fig 7B (cont'd)

Val	Glu	Thr	Thr	Pro	Gln	Asn	Gly	Val	Val	Val	Thr	Asp	Ala	Glu	Ala	
225					230					235					240	
Gly	Ser	Leu	His	Leu	Leu	Glu	Val	Asp	Phe	Ala	Glu	Gly	Ala	Leu	Gln	
			245						250						255	
Arg	Thr	Glu	Lys	Leu	Gln	Gly	His	Leu	Cys	Asn	Pro	Arg	Gly	Val	Ala	
			260					265						270		
Val	Ser	Trp	Leu	Thr	Gly	Ala	Ile	Ala	Val	Leu	Glu	His	Pro	Pro	Gly	
		275					280						285			
Leu	Gly	Ala	Gly	Ala	Gly	Ser	Thr	Ala	Val	Lys	Val	Phe	Ser	Pro	Thr	
	290					295					300					
Met	Gln	Leu	Ile	Gly	Gln	Val	Asp	Thr	Phe	Gly	Leu	Ser	Leu	Phe	Phe	
305					310					315					320	
Pro	Ser	Arg	Ile	Thr	Ala	Ser	Ala	Val	Thr	Phe	Asp	His	Gln	Gly	Asn	
			325						330						335	
Val	Ile	Val	Ala	Asp	Thr	Ser	Ser	Gln	Ala	Val	Leu	Cys	Leu	Gly	Gln	
			340					345						350		
Pro	Glu	Glu	Phe	Pro	Val	Leu	Lys	Pro	Ile	Ile	Thr	His	Gly	Leu	Ser	
		355					360					365				
His	Pro	Val	Ala	Leu	Thr	Phe	Thr	Lys	Glu	Asn	Ser	Leu	Leu	Val	Leu	
		370				375					380					
Asp	Ser	Ala	Ala	His	Ser	Val	Lys	Val	Tyr	Lys	Ala	Asp	Trp	Gly		
385					390					395						

Pat nt Application Data Sheet

Application Information

Application Type:: Provisional

Subject Matter:: Utility

**Suggested
Classification::**

**Suggested Group Art
Unit::**

CD-ROM or CD-R?:: None

Number of CD disks:: 0

Number of copies of CDs:: 0

Sequence submission?:: YES

**Computer Readable
Form (CRF)?::** NO

Number of copies of CRF:: 0

Title:: LAFORA'S DISEASE GENE

Attorney Docket Number:: 9962-51

**Request for Early
Publication?::** NO

Request for Non-Publication?:: NO

Suggested Drawing Figure::

Total Drawing Sheets:: 11

Small Entity?:: NO

Latin Name::

**Variety denomination
name::**

Petition included?:: No

Petition Type::

**Licensed US Govt.
Agency::**

**Contract or Grant
Numbers::**

**Secrecy Order in
Parent Appl.?::** No

Applicant Information

Inventor Authority Type:: Inventor

**Primary Citizenship
Country::** Canada

Status:: Full Capacity

Given Name:: STEPHEN

Middle Name:: W.

Family Name:: SCHERER

Name Suffix::

City of Residence:: Toronto

**State or Prov. Of
Residence::** Ontario

Country of Residence:: CANADA

Street of mailing address:: 60 Mayfield Avenue

City of mailing address:: Toronto

**State or Province of
mailing address::** Ontario

Country of mailing address:: CANADA

Postal or Zip Code of

mailing address:: M6S 1K5

Inventor Authority Type:: Inventor

Primary Citizenship
Country:: Canada

Status:: Full Capacity

Given Name:: BERGE

Middle Name:: A.

Family Name:: MINASSIAN

Name Suffix::

City of Residence:: Toronto

State or Prov. Of
Residence:: Ontario

Country of Residence:: CANADA

Street of mailing address:: 18 Vanderhoof Avenue

City of mailing address:: Toronto

State or Province of
mailing address:: Ontario

Country of mailing address:: CANADA

Postal or Zip Code of
mailing address:: M4G 2H1

Correspondence Information

Correspondence Customer
Number:: 001059

Phone Number:: (416) 364-7311

Fax Number:: (416) 361-1398

E-Mail Address:: vkrichker@bereskinparr.com

Representative Information

**Representative
Customer Number:: 001059**

Domestic Priority Information

Application::	Continuity Type::	Parent Application::	Parent Filing Date::
----------------------	--------------------------	---------------------------------	---------------------------------

Foreign Priority Applications

Country::	Application Number::	Filing Date::	Priority Claimed
------------------	---------------------------------	----------------------	-------------------------

SEQUENCE LISTING

<110> Scherer, Stephen W.
Minassian, Berge A.

<120> Novel Lafora's Disease Gene

<130> 9962-51

<160> 4

<170> PatentIn version 3.1

<210> 1

<211> 2134

<212> DNA

<213> Homo sapiens

<400> 1
gcacaggacg cgccatggcg gccgaagcct cggagagcgg gccagcgctg catgagctca 60
tgcgcgaggc ggagatcagc ctgctcgagt gcaaggtgtg ctttgagaag tttggccacc 120
ggcagcagcg gcgcccgcgc aacctgtcct gcggccacgt ggtctgcctg gcctgcgtgg 180
ccgccctggc gcacccgcgc actctggccc tcgagtgcct attctgcagg cgagcttgcc 240
ggggctgcga caccagcgac tgcctgccgg tgctgcacct catagagctc ctgggctcag 300
cgcttcgcca gtccccggcc gcccatcgcg ccgccccag cgccccgga gccctcacct 360
gccaccacac cttcggcggc tgggggaccc tggtaaccc caccggactg gcgctttgtc 420
ccaagacggg gcgtgtcgtg gtggtgcacg acggcaggag gcgtgtcaag atttttgact 480
cagggggagg atgcgcgat cagtttgagg agaaggggga cgctgccaa gacattaggt 540
accctgtgga tgtcaccatc accaacgact gccatgtggt tgtcactgac gccggcgatc 600
gtccatcaa agtgtttgat ttttttgccc agatcaagct tgtcattgga ggccaattct 660
ccttaccttg ggggtgtggag accacccctc agaatgggat tgtggtaact gatgcggagg 720
cagggtccct gcacctctg gacgtcgact tcgcggaagg ggtccttcgg agaactgaaa 780
ggttgcaagc tcactgtgc aatccccgag ggggtggcagt gtcttggtc accggggcca 840

ttgcggtcct	ggagcacccc	ctggccctgg	ggactggggt	ttgcagcacc	agggtgaaag	900
tgtttagctc	aagtatgcag	cttgtcggcc	aagtggatac	ctttgggctg	agcctctact	960
ttccctccaa	aataactgcc	tccgctgtga	cctttgatca	ccagggaat	gtgattgttg	1020
cagatacatc	tgggccagct	atcctttgct	taggaaaacc	tgaggagttt	ccagtaccga	1080
agcccatggt	cactcatggt	ctttcgcatc	ctgtggctct	taccttcacc	aaggagaatt	1140
ctcttcttgt	gctggacaca	gcatctcatt	ctataaaagt	ctataaagtt	gactgggggt	1200
gatgggctgg	ggagggtccc	tggaatcaga	agcactagt	ctgccattaa	tgaattgttt	1260
aaccctggat	aagtcactta	aactcatcta	tccaggcagg	gataattaaa	accatctggc	1320
agacttacaa	agcttgggac	agttattgga	gattaatcta	ccatttattg	aatgcatact	1380
ctgtgcaagg	aaatttgcaa	atattagctt	atttaatctg	tactatccag	tgaggtaatt	1440
tcttcccccc	caagatagag	tcaagctctg	tcaccaggc	tggagtgcag	aagcatgatc	1500
acagctcact	acagtttcaa	cgtccccgc	tcagggtggtc	cttcacctc	agcctcccaa	1560
gtagctggga	ccacaagtgt	gcattaccac	actcagctaa	tttttgtatt	ttggcagaga	1620
tgggggttca	ccatgttgcc	caggctgggtc	tcaaactcct	gagttcaagc	aatccacctt	1680
cctcggcctc	ccaaagtact	aggagtacag	gcatagccac	ttgctcagcc	ataattttta	1740
ttattaatct	cattgtacaa	gtgagaaaac	tgagaccag	agagcttaag	tgacttcctc	1800
gaggcatag	ttacttactg	ccttagtccc	aatttgaatt	caattctgat	tccaaataag	1860
ttgcgcttaa	ataagacaac	agatgtggga	aaaatatgtg	aatgtgtagt	gttgctatgt	1920
gtactgtctt	tacaagtagc	taattatttt	agcacaaga	tgtgcaaaga	aaggagactt	1980
tatggagagt	tcaggagaaa	aaggattttg	tgggtggccat	cactttcatt	caatttgcca	2040
ctgctctgat	ggcacattag	atgaagttac	tgttgatcct	gagttacgtg	aataagaaaa	2100
acaattgaac	tgcttattaa	aaaagtaaac	atgt			2134

<210> 2

<211> 395

<212> PRT

<213> Homo sapiens

<400> 2

Met	Ala	Ala	Glu	Ala	Ser	Glu	Ser	Gly	Pro	Ala	Leu	His	Glu	Leu	Met
1				5				10					15		

Arg	Glu	Ala	Glu	Ile	Ser	Leu	Leu	Glu	Cys	Lys	Val	Cys	Phe	Glu	Lys	20	25	30	
Phe	Gly	His	Arg	Gln	Gln	Arg	Arg	Pro	Arg	Asn	Leu	Ser	Cys	Gly	His	35	40	45	
Val	Val	Cys	Leu	Ala	Cys	Val	Ala	Ala	Leu	Ala	His	Pro	Arg	Thr	Leu	50	55	60	
Ala	Leu	Glu	Cys	Pro	Phe	Cys	Arg	Arg	Ala	Cys	Arg	Gly	Cys	Asp	Thr	65	70	75	80
Ser	Asp	Cys	Leu	Pro	Val	Leu	His	Leu	Ile	Glu	Leu	Leu	Gly	Ser	Ala	85	90	95	
Leu	Arg	Gln	Ser	Pro	Ala	Ala	His	Arg	Ala	Ala	Pro	Ser	Ala	Pro	Gly	100	105	110	
Ala	Leu	Thr	Cys	His	His	Thr	Phe	Gly	Gly	Trp	Gly	Thr	Leu	Val	Asn	115	120	125	
Pro	Thr	Gly	Leu	Ala	Leu	Cys	Pro	Lys	Thr	Gly	Arg	Val	Val	Val	Val	130	135	140	
His	Asp	Gly	Arg	Arg	Arg	Val	Lys	Ile	Phe	Asp	Ser	Gly	Gly	Gly	Cys	145	150	155	160
Ala	His	Gln	Phe	Gly	Glu	Lys	Gly	Asp	Ala	Ala	Gln	Asp	Ile	Arg	Tyr	165	170	175	
Pro	Val	Asp	Val	Thr	Ile	Thr	Asn	Asp	Cys	His	Val	Val	Val	Thr	Asp	180	185	190	
Ala	Gly	Asp	Arg	Ser	Ile	Lys	Val	Phe	Asp	Phe	Phe	Gly	Gln	Ile	Lys	195	200	205	
Leu	Val	Ile	Gly	Gly	Gln	Phe	Ser	Leu	Pro	Trp	Gly	Val	Glu	Thr	Thr	210	215	220	
Pro	Gln	Asn	Gly	Ile	Val	Val	Thr	Asp	Ala	Glu	Ala	Gly	Ser	Leu	His	225	230	235	240
Leu	Leu	Asp	Val	Asp	Phe	Ala	Glu	Gly	Val	Leu	Arg	Arg	Thr	Glu	Arg	245	250	255	

Leu Gln Ala His Leu Cys Asn Pro Arg Gly Val Ala Val Ser Trp Leu
260 265 270

Thr Gly Ala Ile Ala Val Leu Glu His Pro Leu Ala Leu Gly Thr Gly
275 280 285

Val Cys Ser Thr Arg Val Lys Val Phe Ser Ser Ser Met Gln Leu Val
290 295 300

Gly Gln Val Asp Thr Phe Gly Leu Ser Leu Tyr Phe Pro Ser Lys Ile
305 310 315 320

Thr Ala Ser Ala Val Thr Phe Asp His Gln Gly Asn Val Ile Val Ala
325 330 335

Asp Thr Ser Gly Pro Ala Ile Leu Cys Leu Gly Lys Pro Glu Glu Phe
340 345 350

Pro Val Pro Lys Pro Met Val Thr His Gly Leu Ser His Pro Val Ala
355 360 365

Leu Thr Phe Thr Lys Glu Asn Ser Leu Leu Val Leu Asp Thr Ala Ser
370 375 380

His Ser Ile Lys Val Tyr Lys Val Asp Trp Gly
385 390 395

<210> 3

<211> 3008

<212> DNA

<213> Canis sp.

<220>

<221> CDS

<222> (698)..(1897)

<223>

<220>

<221> misc_feature
<222> (2692)..(2692)
<223> N=any nucleic acid

<220>

<221> misc_feature
<222> (2748)..(2748)
<223> N=any nucleic acid

<220>

<221> misc_feature
<222> (2750)..(2750)
<223> N=any nucleic acid

<220>

<221> misc_feature
<222> (2793)..(2793)
<223> N=any nucleic acid

<220>

<221> misc_feature
<222> (2845)..(2845)
<223> N=any nucleic acid

<220>

<221> misc_feature
<222> (2916)..(2916)
<223> N=any nucleic acid

<220>

<221> misc_feature
<222> (2918)..(2918)
<223> N=any nucleic acid

<220>

<221> misc_feature
<222> (2931)..(2931)
<223> N=any nucleic acid

<220>

<221> misc_feature
<222> (2941)..(2941)
<223> N=any nucleic acid

<220>

<221> misc_feature
<222> (2990)..(2990)
<223> N=any nucleic acid

<400> 3
ccccaaaggcc ccccgggccc ccaggcaacc ccaggccccc aggcaaccga aggccccccg 60
gccccaaaggcc cccaggttc ccggccccaa gaaccaaggcc ccccgggccc ccgccccag 120
caccagcac caagcccccg ccccccggcc caagcaccca gcccagcac ccagcccccg 180
ccccagcccc agccccagca ccagcccccc gcccagcac ccagccccag caccagccc 240
ccgccccagc ccagcccccc gtcccccccc ccagcaccca gcccagccc cagcagcagc 300
accagcagg ggactgcaaa gcgtaggcta cccaggtgg aacaccgtgt tctagttttg 360
ctttgccgtt tgcagcctgg gcgatcgggg gccaccgctc gagcctgttt cccgtcgcg 420
aaagcggagc cgccccggcc cgccccccgc ctgcctgaag gtcacgggccc tgggcctgcg 480
gcgcgcggtg cggcccgcca gcgtccgctc ccgcgcctc cgcagtcagc gcccgcccg 540
ccgcccgggg accgcaggcc gcggccgaga ggctgcgcgc tgcgcccgcg acgtcaggcc 600
ccgccccgcc ccgccccgcc ccgtgaccgg ccccgggccc ggccccggcc ccggcccccg 660

accgagcggc gcccgcggga gcggcggcgg ccgcgcg	atg ggg gcc gaa gcg gcg	715
	Met Gly Ala Glu Ala Ala	
	1 5	
ggg agc ggg cgg gcg ctg cgg gag ctg gtg cgc gag gcc gag gtc agc	763	
Gly Ser Gly Arg Ala Leu Arg Glu Leu Val Arg Glu Ala Glu Val Ser		
	10 15 20	
ttg ctc gag tgc aag gtg tgc ttc gag agg ttc ggc cac cgc cag cag	811	
Leu Leu Glu Cys Lys Val Cys Phe Glu Arg Phe Gly His Arg Gln Gln		
	25 30 35	
cgg cgc ccg cgc aac ctg ccc tgc ggc cac gtg gtg tgc ctg gcc tgc	859	
Arg Arg Pro Arg Asn Leu Pro Cys Gly His Val Val Cys Leu Ala Cys		
	40 45 50	
gtg gcg gcc ctg gcg cac ccg cgg acg ctg gcc ctg gag tgc ccc ttc	907	
Val Ala Ala Leu Ala His Pro Arg Thr Leu Ala Leu Glu Cys Pro Phe		
	55 60 65 70	
tgc cgc cgg gcc tgc cgc ggc tgc gac acc agc gac tgc ctg ccg gtg	955	
Cys Arg Arg Ala Cys Arg Gly Cys Asp Thr Ser Asp Cys Leu Pro Val		
	75 80 85	
ctt cac ctc ctg gag ctc ctg ggc tgc gcg ctg cgc cca gcc ccc gcc	1003	
Leu His Leu Leu Glu Leu Leu Gly Ser Ala Leu Arg Pro Ala Pro Ala		
	90 95 100	
gcc ccc cgc gcc gcc ccc cgc gcc gcc ccc tgc gcc ccg ggc gcc ctc	1051	
Ala Pro Arg Ala Ala Pro Arg Ala Ala Pro Cys Ala Pro Gly Ala Leu		
	105 110 115	
gcc tgc cat cac gcg ttc gga ggc tgg ggg acc ctg gtc aac ccc acg	1099	
Ala Cys His His Ala Phe Gly Gly Trp Gly Thr Leu Val Asn Pro Thr		
	120 125 130	
ggg ctg gcg ctg tgc ccc aag acc ggg cgg gtc gtg gtg gtg cac gac	1147	
Gly Leu Ala Leu Cys Pro Lys Thr Gly Arg Val Val Val Val His Asp		
	135 140 145 150	
ggc agg agg cgg gtc aag atc ttt gac tcc ggg gga gga tgc gcc cat	1195	
Gly Arg Arg Arg Val Lys Ile Phe Asp Ser Gly Gly Gly Cys Ala His		
	155 160 165	
cag ttt gga gag aag ggg gag gct gcc cag gac att agg tac ccc ctg	1243	
Gln Phe Gly Glu Lys Gly Glu Ala Ala Gln Asp Ile Arg Tyr Pro Leu		
	170 175 180	
gac gtc gcc gtc acc aac gac tgc cac gtg gtt gtc acc gac gcc ggc	1291	
Asp Val Ala Val Thr Asn Asp Cys His Val Val Val Thr Asp Ala Gly		
	185 190 195	
gac cgc tcc atc aaa gtg ttt gat ttc ttt ggc cag atc aag ctc gtc	1339	
Asp Arg Ser Ile Lys Val Phe Asp Phe Phe Gly Gln Ile Lys Leu Val		
	200 205 210	
att gga gac cag ttt tcc tta cct tgg ggc gtg gag acc acc cct cag	1387	
Ile Gly Asp Gln Phe Ser Leu Pro Trp Gly Val Glu Thr Thr Pro Gln		
	215 220 225 230	

aat ggg gtc gtg gta act gac gcc gag gca ggg tcg ctg cac ctg ctg	1435
Asn Gly Val Val Val Thr Asp Ala Glu Ala Gly Ser Leu His Leu Leu	
235 240 245	
gaa gtc gac ttt gca gaa gga gcc ctc cag agg act gaa aag ctg caa	1483
Glu Val Asp Phe Ala Glu Gly Ala Leu Gln Arg Thr Glu Lys Leu Gln	
250 255 260	
ggg cat ctg tgc aac ccg cga ggg gtg gcc gtg tcc tgg ctc act ggg	1531
Gly His Leu Cys Asn Pro Arg Gly Val Ala Val Ser Trp Leu Thr Gly	
265 270 275	
gcc att gcg gtc ctg gag cac cct ccg ggg ctg ggg gct ggg gcg ggc	1579
Ala Ile Ala Val Leu Glu His Pro Pro Gly Leu Gly Ala Gly Ala Gly	
280 285 290	
agc acc gcc gtg aag gtg ttc agc cca act atg cag ctg atc ggc cag	1627
Ser Thr Ala Val Lys Val Phe Ser Pro Thr Met Gln Leu Ile Gly Gln	
295 300 305 310	
gtg gat acc ttt ggg ctc agc ctc ttt ttc ccc tct aga ata acc gcc	1675
Val Asp Thr Phe Gly Leu Ser Leu Phe Phe Pro Ser Arg Ile Thr Ala	
315 320 325	
tcc gcc gtg acc ttt gat cac cag ggg aat gtg att gtt gca gat act	1723
Ser Ala Val Thr Phe Asp His Gln Gly Asn Val Ile Val Ala Asp Thr	
330 335 340	
tct agt cag gcc gtc cta tgc ttg gga cag cct gag gaa ttt cca gtc	1771
Ser Ser Gln Ala Val Leu Cys Leu Gly Gln Pro Glu Glu Phe Pro Val	
345 350 355	
ctg aag ccc atc atc acc cat ggt ctt tcc cat cct gtg gca ctg acc	1819
Leu Lys Pro Ile Ile Thr His Gly Leu Ser His Pro Val Ala Leu Thr	
360 365 370	
ttc acc aag gag aat tct ctt ctt gtg ctg gac agt gca gcc cat tcc	1867
Phe Thr Lys Glu Asn Ser Leu Leu Val Leu Asp Ser Ala Ala His Ser	
375 380 385 390	
gta aaa gtc tac aag gct gac tgg ggg taa tgggggtgtgg tgggggtcct	1917
Val Lys Val Tyr Lys Ala Asp Trp Gly	
395	
ggaactgccca ctaatccagt ttaaccctgg atgaattaat cccatctctc gaacggggat	1977
cattataact gcctgacaga cttataaagg ttgaaggtaa ttattaaaga ataataatga	2037
agtctaccgt ttattgagtt atgtgctccc tgtgctagga aactttgcaa atattagctc	2097
agcgtgtcct tacagtggta ccagggagg taatgcccatt cattaatccc attttagaga	2157
tgagaaaact gagaccgag ggtttaagtg attctctgaa ggtcatgttt acttactgtg	2217
acagtcacaa tgggaactct attctgactc cccaatccct tgctcctaag taggataaca	2277
gatgtgagaa aacgacagca tgtgtctata tgtgtgtact gtgtgtactc tctttacagg	2337
tagctatttc tcttggttgg acgtgcagag aaaggagact ttctagagag ttcaagagga	2397

aaaagggtag tgtgatgagc atggacgtga gtgtcattga acttgctggt tctttgatgt 2457
cacagtaggt agaatgactg tggatccttc aactgccctt gggaaaggta aacatgtctg 2517
ttgggacctg gatgtcctcc atcataggaa cccaggaaat actagttggt tgctgcagaa 2577
aggcttgtgt ggacataagt tcaaaactac tgccgaccac cgtacattca cacacctcca 2637
gtgggagatg gctggaagac agtcctgtga caggtctgca ttcatagaac aagangccgc 2697
caccgttggt tcacggcaga atgagtttgc ctgcctcttc ataatctgtg ncnacccgaa 2757
acctttttgt gatagagttt ttctctgtgc catttnaatt tgtcccattg cacacactgt 2817
tttcccctaa ccagctccct tgatgctnag ctagcattta ggccactggt aaaccctgt 2877
atacttcttg agttgaagtt aagctttgac ccagataang nctgctttaa tacntgcagt 2937
cgantggacc gaataagggg gaaatttcag gtgaggtggc cgggttcttt atnaaccggt 2997
tttggtttgt a 3008

<210> 4

<211> 399

<212> PRT

<213> Canis sp.

<220>

<221> misc_feature

<222> (2692)..(2692)

<223> N=any nucleic acid

<220>

<221> misc_feature

<222> (2748)..(2748)

<223> N=any nucleic acid

<220>

<221> misc_feature

<222> (2750)..(2750)

<223> N=any nucleic acid

<220>

```

<221> misc_feature
<222> (2793)..(2793)
<223> N=any nucleic acid
<220>

<221> misc_feature
<222> (2845)..(2845)
<223> N=any nucleic acid
<220>

<221> misc_feature
<222> (2916)..(2916)
<223> N=any nucleic acid
<220>

<221> misc_feature
<222> (2918)..(2918)
<223> N=any nucleic acid
<220>

<221> misc_feature
<222> (2931)..(2931)
<223> N=any nucleic acid
<220>

<221> misc_feature
<222> (2941)..(2941)
<223> N=any nucleic acid
<220>

<221> misc_feature
<222> (2990)..(2990)
<223> N=any nucleic acid
<400> 4

```

```

Met Gly Ala Glu Ala Ala Gly Ser Gly Arg Ala Leu Arg Glu Leu Val
1           5           10           15

```

Arg Glu Ala Glu Val Ser Leu Leu Glu Cys Lys Val Cys Phe Glu Arg
20 25 30

Phe Gly His Arg Gln Gln Arg Arg Pro Arg Asn Leu Pro Cys Gly His
35 40 45

Val Val Cys Leu Ala Cys Val Ala Ala Leu Ala His Pro Arg Thr Leu
50 55 60

Ala Leu Glu Cys Pro Phe Cys Arg Arg Ala Cys Arg Gly Cys Asp Thr
65 70 75 80

Ser Asp Cys Leu Pro Val Leu His Leu Leu Glu Leu Leu Gly Ser Ala
85 90 95

Leu Arg Pro Ala Pro Ala Ala Pro Arg Ala Ala Pro Arg Ala Ala Pro
100 105 110

Cys Ala Pro Gly Ala Leu Ala Cys His His Ala Phe Gly Gly Trp Gly
115 120 125

Thr Leu Val Asn Pro Thr Gly Leu Ala Leu Cys Pro Lys Thr Gly Arg
130 135 140

Val Val Val Val His Asp Gly Arg Arg Arg Val Lys Ile Phe Asp Ser
145 150 155 160

Gly Gly Gly Cys Ala His Gln Phe Gly Glu Lys Gly Glu Ala Ala Gln
165 170 175

Asp Ile Arg Tyr Pro Leu Asp Val Ala Val Thr Asn Asp Cys His Val
180 185 190

Val Val Thr Asp Ala Gly Asp Arg Ser Ile Lys Val Phe Asp Phe Phe
195 200 205

Gly Gln Ile Lys Leu Val Ile Gly Asp Gln Phe Ser Leu Pro Trp Gly
210 215 220

Val Glu Thr Thr Pro Gln Asn Gly Val Val Val Thr Asp Ala Glu Ala
225 230 235 240

Gly Ser Leu His Leu Leu Glu Val Asp Phe Ala Glu Gly Ala Leu Gln
245 250 255

Arg Thr Glu Lys Leu Gln Gly His Leu Cys Asn Pro Arg Gly Val Ala
260 265 270

Val Ser Trp Leu Thr Gly Ala Ile Ala Val Leu Glu His Pro Pro Gly
275 280 285

Leu Gly Ala Gly Ala Gly Ser Thr Ala Val Lys Val Phe Ser Pro Thr
290 295 300

Met Gln Leu Ile Gly Gln Val Asp Thr Phe Gly Leu Ser Leu Phe Phe
305 310 315 320

Pro Ser Arg Ile Thr Ala Ser Ala Val Thr Phe Asp His Gln Gly Asn
325 330 335

Val Ile Val Ala Asp Thr Ser Ser Gln Ala Val Leu Cys Leu Gly Gln
340 345 350

Pro Glu Glu Phe Pro Val Leu Lys Pro Ile Ile Thr His Gly Leu Ser
355 360 365

His Pro Val Ala Leu Thr Phe Thr Lys Glu Asn Ser Leu Leu Val Leu
370 375 380

Asp Ser Ala Ala His Ser Val Lys Val Tyr Lys Ala Asp Trp Gly
385 390 395

Document made available under the Patent Cooperation Treaty (PCT)

International application number: PCT/CA04/001449

International filing date: 30 July 2004 (30.07.2004)

Document type: Certified copy of priority document

Document details: Country/Office: US
Number: 60/491,968
Filing date: 04 August 2003 (04.08.2003)

Date of receipt at the International Bureau: 26 October 2004 (26.10.2004)

Remark: Priority document submitted or transmitted to the International Bureau in compliance with Rule 17.1(a) or (b)



World Intellectual Property Organization (WIPO) - Geneva, Switzerland
Organisation Mondiale de la Propriété Intellectuelle (OMPI) - Genève, Suisse

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☒ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.